Endometrial and Menstrual Blood Mesenchymal Stem/Stromal Cells: Biological Properties and Clinical Application by Bozorgmehr, M. et al.
fcell-08-00497 July 9, 2020 Time: 11:48 # 1
REVIEW
published: 09 July 2020
doi: 10.3389/fcell.2020.00497
Edited by:
Lindolfo da Silva Meirelles,














†These authors have contributed
equally to this work
Specialty section:
This article was submitted to
Stem Cell Research,
a section of the journal
Frontiers in Cell and Developmental
Biology
Received: 31 March 2020
Accepted: 25 May 2020
Published: 09 July 2020
Citation:
Bozorgmehr M, Gurung S,
Darzi S, Nikoo S, Kazemnejad S,
Zarnani A-H and Gargett CE (2020)
Endometrial and Menstrual Blood
Mesenchymal Stem/Stromal Cells:
Biological Properties and Clinical
Application.
Front. Cell Dev. Biol. 8:497.
doi: 10.3389/fcell.2020.00497
Endometrial and Menstrual Blood
Mesenchymal Stem/Stromal Cells:
Biological Properties and Clinical
Application
Mahmood Bozorgmehr1,2†, Shanti Gurung3†, Saeedeh Darzi4,5†, Shohreh Nikoo6†,
Somaieh Kazemnejad7†, Amir-Hassan Zarnani1,8*† and Caroline E. Gargett4,5*†
1 Reproductive Immunology Research Center, Avicenna Research Institute, Academic Center for Education, Culture and
Research (ACECR), Tehran, Iran, 2 Oncopathology Research Center, Iran University of Medical Sciences, Tehran, Iran,
3 Centre for Reproductive Health, Hudson Institute of Medical Research, Melbourne, VIC, Australia, 4 The Ritchie Centre,
Hudson Institute of Medical Research, Melbourne, VIC, Australia, 5 Department of Obstetrics and Gynaecology, Monash
University, Melbourne, VIC, Australia, 6 Immunology Research Center, Iran University of Medical Sciences, Tehran, Iran,
7 Nanobitechnology Research Center, Avicenna Research Institute, Academic Center for Education, Culture and Research
(ACECR), Tehran, Iran, 8 Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran,
Iran
A highly proliferative mesenchymal stem/stromal cell (MSC) population was recently
discovered in the dynamic, cyclically regenerating human endometrium as clonogenic
stromal cells that fulfilled the International Society for Cellular Therapy (ISCT) criteria.
Specific surface markers enriching for clonogenic endometrial MSC (eMSC), CD140b
and CD146 co-expression, and the single marker SUSD2, showed their perivascular
identity in the endometrium, including the layer which sheds during menstruation.
Indeed, cells with MSC properties have been identified in menstrual fluid and commonly
termed menstrual blood stem/stromal cells (MenSC). MenSC are generally retrieved
from menstrual fluid as plastic adherent cells, similar to bone marrow MSC (bmMSC).
While eMSC and MenSC share several biological features with bmMSC, they also show
some differences in immunophenotype, proliferation and differentiation capacities. Here
we review the phenotype and functions of eMSC and MenSC, with a focus on recent
studies. Similar to other MSC, eMSC and MenSC exert immunomodulatory and anti-
inflammatory impacts on key cells of the innate and adaptive immune system. These
include macrophages, T cells and NK cells, both in vitro and in small and large animal
models. These properties suggest eMSC and MenSC as additional sources of MSC
for cell therapies in regenerative medicine as well as immune-mediated disorders and
inflammatory diseases. Their easy acquisition via an office-based biopsy or collected
from menstrual effluent makes eMSC and MenSC attractive sources of MSC for clinical
applications. In preparation for clinical translation, a serum-free culture protocol was
established for eMSC which includes a small molecule TGFβ receptor inhibitor that
prevents spontaneous differentiation, apoptosis, senescence, maintains the clonogenic
SUSD2+ population and enhances their potency, suggesting potential for cell-therapies
and regenerative medicine. However, standardization of MenSC isolation protocols and
culture conditions are major issues requiring further research to maximize their potential
for clinical application. Future research will also address crucial safety aspects of eMSC
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and MenSC to ensure these protocols produce cell products free from tumorigenicity
and toxicity. Although a wealth of data on the biological properties of eMSC and MenSC
has recently been published, it will be important to address their mechanism of action in
preclinical models of human disease.
Keywords: endometrium, menstrual blood, culture expansion, perivascular MSC, eMSC, MenSC, cell therapy,
immunomodulation
INTRODUCTION
Almost all human tissues contain a small resident population
of perivascular mesenchymal stem/stromal cells (MSC) (Crisan
et al., 2008). MSC have also been identified in a wide
variety of small and large mammalian species (Rozemuller
et al., 2010), although these have been studied to a lesser
degree. Here we discuss a novel source of MSC from
the highly regenerative endometrial lining of the uterus
(Figure 1A), accessible by biopsy in an office-based procedure
without an anesthetic, or non-invasively from menstrual blood
(Figure 1B) (Ulrich et al., 2013). This review will focus on
the biological properties and recent functional characterization
of endometrial MSC (eMSC) and menstrual blood MSC
(MenSC). The reader is referred to a recent comprehensive
review providing greater details on earlier studies describing
the identification and early characterization of endometrial
MSC, MenSC and endometrial stromal fibroblasts (Gargett
et al., 2016). Both epithelial progenitors and MSC have been
identified in human and mouse endometrium, however, it is
the endometrial and menstrual blood MSC that comprise the
topic of this review.
Recently the MSC field has been criticized, due to the poor
characterization of MSC from various sources, which has resulted
in underwhelming outcomes of many clinical trials using MSC
(Sipp et al., 2018). Counter arguments reiterate the importance
of using the appropriate definition of the cells under study
(i.e., perivascular MSC versus fibroblasts) (Galipeau et al., 2019).
Integrated transcriptomic profiling of human MSC from different
tissues show their segregation by tissue of origin (Roson-Burgo
et al., 2016; Menard et al., 2020) and distinct tissue-specific MSC
immune signatures that are similar between fresh and cultured
MSC from the same tissue source (Menard et al., 2020). Herein
we will distinguish between perivascular eMSC and endometrial
stromal fibroblasts. We will also differentiate between potential
regenerative “stem cell” properties and immunomodulatory
function of both eMSC and MenSC. It has become clear that
the regenerative properties of MSC are mainly due to the
trophic factors they secrete. These stimulate endogenous cells
to repair damaged tissues, rather than MSC functioning as true
stem cells (Bianco et al., 2013). MSC are reparative rather than
regenerative. It is also recognized that MSC have profound
immunomodulatory effects on innate and adaptive immune cells
that promote healing by reducing inflammation and immune
responses (Galipeau and Sensebe, 2018). In this review, we
recognize these important developments in the MSC field and our
review on endometrial and menstrual blood MSC and fibroblasts
has been structured around these themes.
Human endometrium is a dynamic remodeling tissue,
undergoing cycles of growth, differentiation and shedding on
a monthly basis as part of the menstrual cycle (Gargett et al.,
2012). These dynamic processes occur about 400 times in women
until menopause (Jabbour et al., 2006). During menstruation,
the upper functional layer of endometrial tissue sloughs off
and the tissue fragments exit the body in menstrual blood,
leaving a residual 1–2 mm of endometrial tissue (basalis)
overlying the myometrium (uterine muscle) (Figures 1A–C).
The raw surface rapidly reepithelializes and the new functional
layer (functionalis), comprising epithelial-lined glands and an
extensive vascularized stroma regenerates under the influence
of rising, circulating estrogen levels (Gargett et al., 2008)
in the next cycle. Atrophic postmenopausal endometrium,
which transcriptionally resembles cycling basalis endometrium
(Nguyen et al., 2012), also regenerates a functionalis-like
layer when women take estrogen-only hormone replacement
therapy. MSC can be harvested from this regenerated tissue
(Ulrich et al., 2014b).
HUMAN ENDOMETRIAL MSC
Endometrial MSC were first identified as clonogenic stromal
cells, comprising 1.3% of stromal fibroblasts harvested from
hysterectomy tissue, which contains both functionalis and
basalis endometrium (Chan et al., 2004). The large stromal
colonies, comprised densely packed small cells with a fibroblast-
like morphology and distinguishable from self-limiting small,
sparsely packed colonies, likely originated from colony forming
units-fibroblast (CFU-F) and do not vary in frequency during
the menstrual cycle. This and their presence in postmenopausal
endometrium indicate hormone independence of endometrial
CFU-F (Schwab et al., 2005; Ulrich et al., 2014b). In comparison
to single small colonies, individual large CFU-F showed high
proliferative capacity, undergoing 30 population doublings (PD)
and producing > 600 billion cells (Gargett et al., 2009). Single
large endometrial CFU-F underwent self-renewal in vitro by
serial cloning at very low seeding densities (5–10 cells/cm2)
and differentiated into adipocytes, chondrocytes, myocytes and
osteocytes (Gargett et al., 2009). They also expressed the
classic pattern of International Society for Cellular Therapies
(ISCT) markers (Table 1). These properties indicate that human
endometrium contains a small population of MSC.
Markers of eMSC
eMSC were identified as perivascular cells by comparing cloning
efficiencies of endometrial stromal cells purified using flow
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FIGURE 1 | Ovarian and Menstrual cycle, structure of human endometrium and its shedding during menstruation. (A) Schematic showing human ovarian hormonal
changes corresponding with endometrial growth, differentiation and shedding, during the menstruation, proliferative and secretory phases, respectively, of a
menstrual cycle. (B) Schematic showing endometrial tissue collection from human endometrium as an office-based procedure using a Pipelle endometrial suction
catheter and menstrual fluid using a menstrual cup. (C) Histological sections stained with H&E of pre-menopausal human endometrium during the growth
(proliferative), differentiation (secretory) and menses stages of the menstrual cycle showing the functionalis, basalis and myometrial layers of the endometrium.
*Endometrial tissue breakdown early in the menstrual stage, leaving behind an intact basalis layer. Menstrual blood showing endometrial tissue fragments comprising
endometrial stroma, glands and blood cells. Dotted lines define the layers of the endometrium. g, glands. Reproduced with permission from Figure 1A from Elsevier
(Gargett et al., 2008) and Figure 1C from Oxford University Press (Nguyen et al., 2012).
cytometry for several surface markers used for bone marrow
MSC (Figure 2A) (Schwab et al., 2008). Most CFU-F were
from cells co-expressing CD140b and CD146 (Schwab and
Gargett, 2007). CD140b+CD146+ cells, comprising 1.5% of
endometrial stromal cells, were enriched eightfold for CFU-F
over unsorted stromal cells and fulfilled the ISCT MSC
criteria (Dominici et al., 2006). Their perivascular identity was
revealed in both the basalis and functionalis (Figures 2B,J),
indicating that CD140b+CD146+ eMSC could be isolated from
endometrial biopsies and would be shed in menstrual blood
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(Darzi et al., 2016). Gene profiling CD14b+CD146+ eMSC
versus CD140b+CD146− endometrial fibroblasts showed 762
differentially expressed genes (Spitzer et al., 2012), indicating that
perivascular eMSC are distinct from endometrial fibroblasts as
for other MSC types (Menard et al., 2020).
Similar to bone marrow MSC, perivascular eMSC are also
MSCA-1+ (Sobiesiak et al., 2010), a marker antibody that
identifies tissue non-specific aminopeptidase (TNAP), however,
this marker is not useful for sorting eMSC as it also marks
glandular epithelial cells (Figures 2G,H).
To identify a single marker of perivascular eMSC, endometrial
stromal cell suspensions were screened with a panel of
perivascular and other novel antibodies by flow cytometry and
immunohistochemistry of human endometrium (Masuda et al.,
2012). Using this strategy, the W5C5 antibody identified a
robust marker of stromal cells from pre- and postmenopausal
endometrium with MSC properties, enriching clonogenic cells
18-fold over W5C5− fibroblasts (Masuda et al., 2012; Ulrich
et al., 2014b). Sushi Domain-containing 2 (SUSD2) was the
antigen identified by the W5C5 antibody (Sivasubramaniyan
et al., 2013). SUSD2+ cells comprise 4.1% of endometrial
stromal cells and in addition to satisfying the ISCT criteria, they
reconstituted stromal tissue in vivo under the kidney capsule of
NOD-Scid γ (NSG) mice. Non-ISCT markers also expressed by
freshly isolated SUSD2+ eMSC include CD117, CD140b, CD146,
and STRO-1 (Figure 2E). More clonogenic cells were present
in the SUSD2+CD146+ and SUSD2hi subpopulations than in
the CD140b+CD146+ co-expressing population (Masuda et al.,
2012). SUSD2 enables prospective isolation of eMSC from freshly
isolated cell suspensions using magnetic bead sorting, providing
a more clonogenic population than obtained by flow cytometry
sorting, which adversely affects cell viability (Masuda et al., 2012).
This is an important consideration for clinical translation.
The specific markers of eMSC show that these cells are located
around blood vessels in both the functionalis (Figures 1, 2)
indicating they are shed into menstrual fluid as the functionalis
breaks down during menstruation (Figure 1B). Similarly, stromal
fibroblasts are shed into menstrual fluid. Both eMSC and
stromal fibroblasts (MenSC) are shed in numbers proportionate
to their composition in endometrial functionalis tissue, with
eMSC comprising a minority subpopulation. The adult stem
cell properties of human eMSC suggest that stromal fibroblasts
are their progeny, and to date the only evidence comes from
xenografting SUSD2+ eMSC into immunocompromised mice
where stromal tissue was generated (Masuda et al., 2012).
Differentiation of eMSC
Physiologically, eMSC around spiral arterioles differentiate into
decidual cells under influence of the pregnancy hormone,
progesterone, during the secretory stage of the menstrual cycle
(Gellersen and Brosens, 2014). This decidual differentiation
spreads to the stromal fibroblasts beneath the luminal epithelium.
Decidual cells are specialized secretory cells that provide an
immunoprivileged environment for an implanting embryo
to establish the materno-fetal interface. Subpopulations of
eMSC and stromal fibroblasts undergo senescence during the
differentiation process (Lucas et al., 2016) and when no
embryo implants, progesterone levels fall and menstruation
ensues (Figure 1).
Transcriptional profiling of endometrial SUSD2+ eMSC and
SUSD2− stromal fibroblasts revealed a distinct gene signature
for both cell types following decidual differentiation in vitro
(Murakami et al., 2014). Known and novel perivascular genes
were upregulated in SUSD2+ eMSC, which produced lower levels
of inflammatory mediators and chemokines in vitro compared
to SUSD2− stromal fibroblasts. Similarly, the inflammatory gene
signature of freshly isolated and cultured CD140b+CD146+
eMSC had fewer transcripts than CD140b+CD146− endometrial
stromal fibroblasts (Barragan et al., 2016). Upon decidualization
(differentiation) induction SUSD2+ eMSC and SUSD2− stromal
fibroblasts showed greater divergence of their respective
secretomes, with the eMSC producing much higher levels of
leukemia inhibitory factor and the chemokine CCL7 than stromal
fibroblasts. These varying features highlight differences between
perivascular eMSC and stromal fibroblasts.
Embryologically, endometrium derives from the mesoderm.
Thus, it is not unexpected that endometrial MSC and stromal
fibroblasts can be induced to differentiate into mesodermal
lineages. Differentiation of eMSC into classic mesodermal
lineages in vitro as recommended by the ISCT has been
shown for clonogenic endometrial stromal cells, SUSD2+ and
CD140b+CD146+ cells (Schwab and Gargett, 2007; Gargett et al.,
2009; Masuda et al., 2012; Su et al., 2014). Endometrial stromal
fibroblasts also show similar mesodermal lineage differentiation,
as do bone marrow-derived stromal cells (Haniffa et al., 2009).
The reader is referred to table III in Gargett et al. (2016) for
a comprehensive list of studies describing mesodermal lineage
differentiation of eMSC and endometrial stromal fibroblasts.
Differentiation into endodermal lineages include hepatocytes
from clonogenic eMSC in vitro (Yang et al., 2014) and insulin-and
glucagon-secreting pancreatic lineages both in vitro and in vivo
from endometrial stromal fibroblasts (Li et al., 2010; Santamaria
et al., 2011). Similarly, cultured endometrial fibroblasts have
been differentiated into ectodermal lineages such as dopamine-
secreting neurons in vitro and in vivo, where they may have also
induced endogenous neural cell secretion (Wolff et al., 2011).
Oligodendrocyte progenitor cells have been differentiated from
endometrial stromal fibroblasts (Ebrahimi-Barough et al., 2013).
It is not known if eMSC differentiate into ectodermal lineages.
Endometrial MSC in Other Species
The dynamic nature of the endometrium is not limited
to humans. Endometrium of other species also undergo
proliferation and differentiation, and endure high levels of
regeneration during their reproductive life (Rozemuller et al.,
2010; Lara et al., 2018). No animal models can replace humans,
however, they provide preclinical models bridging the gap
between the in vitro potential of MSC and future clinical use
in humans. The identification of endometrial stromal/stem cells
in non-human species has made this possible. Mammalian MSC
have been identified in the endometrium (Lara et al., 2018) of
mice (Chan and Gargett, 2006; Cervello et al., 2007), guinea
pig (Ordener et al., 1993), pig (Miernik and Karasinski, 2012;





















TABLE 1 | Comparison of phenotypic markers of endometrial, menstrual, bone marrow, and adipose tissue MSC isolated by plastic adherence or by SUSD2 or CD34 cell sorting.
Markers (% positive cells)
MSC type CD29 CD31 CD34 CD44 CD45 CD73 CD90 CD105 CD140b CD146 SUSD2 STRO1 SSEA4 OCT4 HLA-DR References
Pericyte CD146+CD140b+
eMSC in SFM




11.6 5.3 – 77 4.7 99 71 99 85 28 95 60 – – – Masuda et al., 2012
Perivascular SUSD2+ eMSC in
SM
93 2.3 0.5 93 – 99.9 98 99.5 50 1–2 – 0.9 – – 0 Darzi et al., 2016
Perivascular SUSD2+ eMSC in
SFM
– – – - – – – – 53 1 69 – – – – Gurung et al., 2015
Perivascular SUSD2+ bmMSC
in SM




– 26 5 70 90 – 0 20 – 4 – – – – 22 Busser et al., 2015
Perivascular SUSD2+ bmMSC
in SM
– 5.3 1.4 83 1.6 – 81 64 – 95 – – – – 1.7 Busser et al., 2015
CD34+ adMSC, freshly isolated – 38 78 81 57 – 39 28 – 41 – – – – 10 Busser et al., 2015
CD34+ adMSC in SM – 6.7 17 98 5.8 – 56 79 – 13 – – – – 4.9 Busser et al., 2015
Plastic adherent, passaged,
CD117+ MenSC in SM
65 – 5.7 99.8 2.1 – 99.8 99.8 – – – – 90 – 1.6 Patel et al., 2008
Plastic adherent MenSC 99.6 – 0.7 99.4 0.8 99.2 93.1 99.6 – 74.9 – 5.6 – 97.5 0 Musina et al., 2008
Plastic adherent bmMSC >95 – 0 97.8 0 ≥ 90 ≥90 ≥ 90 ≥95 15–20 – 3.8 – 0 0 Vogel et al., 2003;
Musina et al., 2008;
Bourin et al., 2013
Plastic adherent adMSC >95 – 0 64 0 25 55 5 – 21 – 0 – – 1 Gronthos et al.,
2001; Mitchell
et al., 2006
Adapted from Darzi et al. Stem Cells Translational Medicine 2016 (Darzi et al., 2016) with permission from John Wiley and Sons Publishers. adMSC, Adipose derived MSC; bmMSC, Bone marrow MSC; HLA-DR, Human
Leukocyte Antigen DR; MenSC, Menstrual blood MSC; MSC, Mesenchymal Stem/Stromal cell; SFM, DMEM/F12 Serum Free Medium supplemented with EGF and FGF2; SM, DMEM/F12 serum medium contains 10%
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FIGURE 2 | Clonogenic endometrial MSC identified using various surface markers. Surface markers (A) CD146, (B) co-expression of CD140b/CD146, SUSD2 (red)
in (C) pre-menopausal and (D) postmenopausal endometrium, showing no colocalization with ERα (green), (E) STRO-1 and (F) EphA3 (red, black arrows), mark
clonogenic perivascular eMSC. (G) MSCA-1 (TNAP) detected by the W8B2 antibody is expressed by both perivascular and (H) epithelial cells in the human
endometrium. (I) CD271 (red) adventitial perivascular cells mark clonogenic cells in ovine endometrium. (J) Schematic of endometrium showing location of
endometrial MSC around the vessels. (K) Schematic enlargement of blood vessels from (J) showing different vascular cell types in the endometrium. Human
CD140b+CD146+ cells are pericytes (pink cytoplasm), and SUSD2, STRO-1, and EphA3 cells are perivascular cells (yellow cytoplasm). Ovine CD27+ cells are
adventitial cells (violet cytoplasm). Mouse CD34+KLF4+ and LRC cells are also represented by perivascular cells (yellow cytoplasm). Images reprinted with
permission from: (A,E) Figures 1E, 4C from Oxford University Press (Schwab et al., 2008), (B) Figure 4I from Oxford University Press (Schwab and Gargett, 2007),
(C) Figure 1A from Bioscientifica (Yang et al., 2019), (D) Figure 4A from Oxford University Press (Ulrich et al., 2014b), (F) Figure 1A from Public Library of Science
(To et al., 2014), (G,H) Figures 5C,D from Mary Ann Liebert (Sobiesiak et al., 2010), (I) Figure 5D from Public Library of Science (Letouzey et al., 2015) and (K)
Figure 2 from Wiley Online Library (Darzi et al., 2016).
Bodek et al., 2015), sheep (Letouzey et al., 2015; Emmerson
et al., 2019), cow (Cabezas et al., 2014), goat (Tamadon et al.,
2017), horse (Cabezas et al., 2018) and non-human primates
(Padykula et al., 1989; Wolff et al., 2015) (Table 1). Label-
retention, plastic adherence or specific surface markers have been
used to isolate endometrial MSC and demonstrate properties
similar to human eMSC and bmMSC.
Murine Label-Retaining Stromal Fibroblasts
Quiescent stem-like endometrial stromal cells were first identified
in mice as bromodeoxyuridine label-retaining cells (LRC), which
accounted for 6% of the population after 12 weeks of chase
in normal cycling mice (Chan and Gargett, 2006). They were
localized adjacent to luminal epithelium, near blood vessels and
at the endometrial-myometrial junction, similar to their basalis
location in human endometrium (Schwab and Gargett, 2007).
Stromal LRCs were both CD31− and CD45−, indicating they
were neither endothelial cells or leukocytes, and perivascular
LRCs were αSMA+ (Chan and Gargett, 2006). Approximately
16% expressed estrogen receptor-α (ER-α) and were recruited
into cell-cycle following estrogen stimulation indicating their
involvement in cyclical endometrial regeneration (Chan and
Gargett, 2006; Chan et al., 2012). LRCs were also positive for
stem cell markers c-Kit and Oct4 (Cervello et al., 2007). However,
stem-cell antigen-1 (Sca-1) was not expressed in stromal LRCs
(Chan and Gargett, 2006).
Recently, CD34+KLF+ endometrial stromal stem/progenitor
cells were identified in the perivascular region in the
endometrium of a menstruating mouse model (Yin et al.,
2019). They expressed the smooth muscle marker, SM22α, and
vimentin and upon estrogen stimulation trans-differentiated
into gland-like structures lined with E-cadherin-expressing
epithelial cells. SUMO-endopeptidase-1 (SENP1)-deletion in
SM22α+cells induced SUMOylation and activation of ERα
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which promoted SM22α+CD34+KLF4+ cell proliferation and
transdifferentiation into endometrial epithelium via cyclin D1.
Mice share ∼85% of protein-coding regions with humans and
have 99% genetic similarity (NIH, 2010), their small size and the
development of transgenic humanized mice allow their utility as
cost-effective models. More research on mouse eMSC isolation
and characterizationis warranted.
Ovine eMSC
Endometrial stromal fibroblasts have been isolated from Fars
native sheep uteri as plastic adherent cells (Ghobadi et al.,
2018) or clonogenic cells from Border-Leicester-Marino ewes
(Letouzey et al., 2015). Plastic adherent cells expressed CD73
but not CD34, with osteogenic and adipogenic differentiation
potential and karyotype stability over four passages. Population
doubling times were directly related to the cell seeding density
and inversely to age of the ewe (Table 2). Clonogenic stromal
cells were enriched using CD271+CD49f− surface markers,
showing properties similar to bmMSC and human eMSC,
with greater clonogenicity, self-renewal by serial cloning
compared to CD271−CD49f− fibroblasts, and differentiated into
adipogenic, myogenic, osteogenic and chondrogenic lineages.
Apart from CD271, human MSC markers CD44, CD90, CD140b,
and CD146 did not cross react with ovine eMSC. The lack
of specific ovine marker antibodies has hampered further
surface phenotype characterization. Although in a perivascular
location, ovine eMSC unlike their human counterpart, were
not located in close apposition to vWF+ endothelial cells.
Neither did they co-localize with αSMA suggesting they were
not pericytes, but rather perivascular adventitial cells, a cell
population with similar properties to MSC (Corselli et al.,
2012; Crisan et al., 2012). The ability to purify characterized
ovine eMSC has enabled the investigation of their use in
uro-gynecological disorders such as pelvic organ prolapse
(POP) (Letouzey et al., 2015; Emmerson et al., 2019). The
domestic ewe has proven a good large animal model because
they develop spontaneous POP after vaginal delivery with
incidence increasing with parity, similar to women (Couri
et al., 2012; Young et al., 2017). Autologous ovine eMSC in
a gelatin hydrogel applied onto a polyamide scaffold and
implanted into the vagina of the ovine POP model survived
for at least 30 days, modulated the inflammatory response,
promoting good tissue integration with no postoperative
mesh-exposure (Emmerson et al., 2019), one of the main
complications associated with human transvaginal mesh
(Frankman et al., 2013).
Non-human Primate Endometrial Stromal Cells
Endometrial-derived stromal cells from the non-human
primate, green monkey engrafted and differentiated into
neuron-like cells when injected into the striatum of males
with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)
induced Parkinson’s disease (Wolff et al., 2015). The expanded
cells used expressed CD140b, CD146, and CD90, but were
otherwise not characterized (Wolff et al., 2015), possibly
due to lack of suitable antibodies. The differentiated cells
expressed tyrosine hydrolase, a rate limiting enzyme for
L-DOPA synthesis, proliferated and produced dopamine
metabolites indicating their potential use in cell-based therapies
(Wolff et al., 2015). Although non-human primates are ideal
for simulating human diseases due to their phylogenetic
similarity, their utility in research raises ethical, practical and
financial issues.
MENSTRUAL BLOOD MSC (MenSC)
Menstrual blood is a readily accessible, non-invasive source
of large numbers of endometrial stem/stromal cells (MenSC)
(Ulrich et al., 2013; Darzi et al., 2016), easily collected using a
menstrual cup (Figure 1B) (Musina et al., 2008; Patel et al., 2008;
de Carvalho Rodrigues et al., 2012). Menstrual blood contains
fragments of shedding endometrial tissue (Figure 1C) which
is cultured directly onto plastic similar to bmMSC. Adherent
MenSC have typical stromal fibroblast morphology and rapidly
propagate with a doubling time of 18–36 h (Meng et al., 2007;
Patel et al., 2008). MenSC have higher proliferative capacity,
30–47 PD before senescence, compared to bmMSC, which are
generally limited to ∼20 PD (Cui et al., 2007; Allickson et al.,
2011). MenSC yield is 2–4-fold higher compared to bmMSC
(Alcayaga-Miranda et al., 2015a). As for other adult stem cells,
the lifespan of MenSC is relatively short in comparison with
human embryonic stem cells (hESC). MenSC only maintain 50%
of their telomerase activity at passage 12 compared to hESCs.
However, MenSC have more telomerase activity than bmMSC
(Patel et al., 2008), perhaps due to the regenerative capacity of
the endometrial stroma.
Besides shed endometrial tissue fragments, menstrual fluid
also contains peripheral blood. The source of MSC in menstrual
fluid could be from bone marrow as well as endometrium.
However, peripheral blood contains exceedingly rare bmMSC, as
demonstrated by CFU-F analysis. Just 2 CFU-F were found in
peripheral blood from 10 patient samples at a frequency of 0–1
CFU-F per 4 × 107 nucleated cells (Kuznetsov et al., 2001). In
contrast, menstrual fluid from 18 healthy women contains 600
CFU-F per ml (Alcayaga-Miranda et al., 2015a), suggesting that
these CFU-F are derived from the endometrial fragments rather
than circulating bone-marrow-derived MSC. Rigorous lineage
tracing in chimeric mouse models has also shown that bone
marrow stem cells do not contribute to endometrial stromal
lineages (Ong et al., 2018). Thus MenSC, comprising mainly
endometrial stromal fibroblasts and a small proportion of eMSC
found in menstrual fluid are derived from sloughing endometrial
tissue rather than non-shedding bone marrow stroma.
Markers of MenSC
MenSC possess the classic ISCT bmMSC markers and are
positive for HLA-ABC, negative for HLA-DR and do not express
hematopoietic lineage markers (Cui et al., 2007; Meng et al.,
2007; Darzi et al., 2012; Kazemnejad et al., 2012; Khanjani
et al., 2014; Khanmohammadi et al., 2014). MenSCs, similar to
clonogenic eMSC, differ from bmMSC as they do not express
STRO-1 (Cui et al., 2007; Meng et al., 2007; Patel et al., 2008;
Schwab et al., 2008; Khanmohammadi et al., 2014). Another
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TABLE 2 | Endometrial MSC and stromal fibroblasts with MSC properties in mammalian species.
Animal Cell type Properties References
Cow Plastic adherent
stromal cells from early
and late luteal phasea
• Clonogenic, 0.5–1% cloning efficiency, some alkaline phosphatase positive
• Fibroblastic morphology. PDT 20–24 h
• Uterine tissue: Express Stat3, Cd44, Cd117, Oct4, and Sox2 but not Nanog. Nuclear Oct4
and Sox2.
• Primary culture: Express Oct4 mRNA, and Sox2 mRNA and protein but not Nanog.
• Differentiation: Osteocytes and Chondrocytes (late luteal phase).
Cabezas et al., 2014
Goat Plastic adherent
stromal cells
• Fibroblastic morphology. Clonogenic, PDT ∼ 50–53 h in anestrus stage.
• Differentiation: Adipocytes, Osteocytes and Chondrocytes
• Stable karyotype during culture expansion
Tamadon et al., 2017
Guinea pig Plastic adherent
stromal cells
• Primary culture: Positive for vimentin, ER and PR; negative for cytokeratin.
• Proliferation ↑by EGF and insulin in serum free media.
• No effect of ovarian hormones in cell growth despite expression of hormone receptors.
• Cultured cells secreted ∼30 different proteins.
Chaminadas et al.,
1986; Mahfoudi et al.,




• Clonogenic, highly proliferative cells, PDT 46.4 ± 3.4 h.
• Differentiation: Osteocytes and Chondrocytes
• Express CD29, CD44, CD90, CD105, MHC class-I but not MHC-II and CD45
• Migrate to chemo-stimulant.
• Intrauterine infusion of autologous mucin − stromal cells: survived up to 24 h.
Cabezas et al., 2018





• D3 postnatal BrdU labeling, 12 week-chase; 6% BrdU+ stromal cells.
• Location: Perivascular, endometrial-myometrial junction, beneath luminal epithelium
• BrdU+ LRC: Some are α-SMA+, ERα+ (16%) and Ki-67+ (12%) in response to exogeneous
estrogen.
• Some co-express c-Kit and OCT4. Do not express C31, Sca-1 and CD45
• Express SM22α and vimentin.
• Proliferate ↑, migrate to injured epithelium and undergo MET upon 17-β estradiol
stimulation.
• SUMOylation augments ERα transcriptional activity with ↑ proliferation and ↓ apoptosis.
Chan and Gargett,
2006; Chan et al., 2012
Cervello et al., 2007
Yin et al., 2019
Monkey Plastic adherent
stromal cells
• Expanded cells are uncharacterised.
• Differentiation: Tyrosine hydrolase-expressing neural-like cells in vivo
• In vivo: ↑ level of dopamine metabolite HVA in PD model.
Wolff et al., 2015
Pig Plastic adherent
stromal cells
• Clonogenic, 0.035% clonal efficiency.
• Express CD29, CD44, CD144, CD105, CD140b and CD31 and pluripotency genes
NANOG and OCT4.
• Differentiation: Osteocytes, Adipocytes and Chondrocytes.
• Highly proliferative compared to adipose-derive MSC.
• Express CD29, CD73, CD90, and CD105 but not CD34 and CD45.
• Wnt pathway activation: ↓large colonies and ↑ small colonies. ↓ MSC surface markers.
Osteogenic but not adipogenic differentiation.
• Wnt pathway inhibition: Clonal efficiency unchanged, MSC markers ↑.
• Higher growth rate than AD-MSC.
• Express CD73, CD90, and CD105 but not CD34 and CD45.
• CD105+ cultured cells differentiation: cardiomyocyte- and insulin-producing β cell-like cells.
Miernik and Karasinski,
2012
Bukowska et al., 2015




• Express CD73 but not CD34 and stable karyotype over four passages.
• PDT ∼21 h immature and ∼45 h mature ewes. PDT α cell density
• Differentiation: Osteocytes, Adipocytes, and Chondrocytes.
• Location: adventitia of arterioles and venules. CD271+ αSMA− cells (Figure 2I).
• Self-renewal by serial cloning in vitro, 5.5% cloning efficiency.
• High proliferative, PD time 18.7 h.
• Differentiation: Osteocytes, Adipocytes, Chondrocytes and Myocytes.
• Express human surface markers CD271 but not CD140b, CD44, CD90, and CD146.
• Autologous eMSC on gelatin/polyamide mesh survived 30 d in a sheep model of vaginal
prolapse.
• ↑COL1A1, COL3A1, FBN5, ELN, and elastin.
• ↓myofibroblasts and inflammatory response to mesh.
• ↓ disrupted muscularis and ↑ elastin fibers
• ↑mesh stiffness, compressive extensions, breaking load and no exposure.
Ghobadi et al., 2018;
Letouzey et al., 2015;
Emmerson et al., 2019
aLuteal phase is the progesterone dominant phase of the estrus cycle; AD-MSC, adipose MSC; ER, estrogen receptor; MET, mesenchymal epithelial transition; PD,
Parkinson disease; PDT, population doubling time; PR, progesterone receptor.
difference is that MenSCs highly express cytoplasmic OCT-
4 (Borlongan et al., 2010) which is not expressed by eMSC
(Gurung et al., 2015; Gurung et al., 2018b) or conventional
bmMSC. Several inconsistencies in MenSC phenotype have
been observed for pluripotency markers c-KIT and SSEA-
4. Some have reported these markers in isolated MenSCs
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(Patel et al., 2008; Borlongan et al., 2010), while others were
negative (Cui et al., 2007; Hida et al., 2008; Musina et al., 2008;
Khanjani et al., 2015). Others observed a different pattern of
these markers in isolated MenSC (Meng et al., 2007; Musina
et al., 2008; Darzi et al., 2012; Kazemnejad et al., 2012)
including expression of SSEA-4 and/or NANOG in some c-KIT+
cells from cultured menstrual blood (Meng et al., 2007; Patel
et al., 2008; Borlongan et al., 2010). Heterogeneity of MenSs
cultures may explain these disparities, resulting from differences
in menstrual blood sampling day, collection technique and
enrichment protocol.
Mesodermal Lineage Differentiation
MenSC have been induced to differentiate into mesodermal
lineages characteristic of bmMSC (Table 3) to satisfy the minimal
criteria for MSC. Similar to marker expression, the degree
of MenSC differentiation into mesodermal lineages varies and
is dependent on the isolation method (Meng et al., 2007;
Darzi et al., 2012; Kazemnejad et al., 2012; Khanjani et al., 2014;
Khanjani et al., 2015). MenSCs isolated by density gradient
centrifugation and plastic adherence have lower capacity to
differentiate toward osteoblasts compared to bmMSC using
both cytochemical and molecular analyses (Darzi et al., 2012).
In contrast, c-KIT+ MenSC possessed similar differentiation
capacity to bmMSC (Patel et al., 2008), although, Alizarin red
alone without quantification was used. It is unknown whether
c-KIT-sorted MenSC have osteogenic differentiation ability.
Adipogenic differentiation of MenSC isolated by density
gradient centrifugation and plastic adherence is limited when
assessed by Oil-red O staining (Musina et al., 2008) and
significantly lower than umbilical cord MSC (Jin et al., 2013)
and bmMSC (Khanmohammadi et al., 2014). Fortification of
adipogenic induction medium with rosiglitazone promoted
MenSC differentiation into adipocytes as analyzed by
molecular and cytochemical techniques (Khanmohammadi
et al., 2014). Purifying cultured MenSC using the c-KIT
TABLE 3 | Comparison of in vitro differentiation capability of menstrual blood- versus bone marrow-derived mesenchymal stem/stromal cells.
Target lineage Differentiation medium Evaluation Results References
Chondrocyte FCS, FGF2, sodium pyruvate, TGFβ3,
BMP6, Dex, ITS+1, and ascorbic acid
sGAG Assay, IF, RT-PCR • High COL2, proteoglycans expression
similar to bmMSC
• different COL9A1 and SOX92A1 to bmMSC
Khanmohammadi
et al., 2012
Osteoblast FCS or HPR, Dex, ascorbic acid, and
β-glycerophosphate
Alizarin red, RT-PCR • ↓ mineralization than bmMSC
• Comparable PTHR, OCN but lower ALP in
HPR medium compared to bmMSC.
Darzi et al., 2012
Adipocyte FBS, Dex, rh-Insulin, IBMX, Indomethacin
and ATRA (3 sequential protocols)
Oil red staining, RT- PCR • Lower differentiation capability compared to
bmMSC for all protocols
Khanmohammadi
et al., 2014




Cardiomyocyte FBS or serum free
medium ± 5-aza, ± FGF2 (2 protocols)
IF, RT-PCR • Similar ↑ late-stage cardiac markers under
5-aza and FGF2 versus 5-aza alone
• ↑ GJA1 and TNNT2 in MenSCs while ↑
GJA1 in bmMSC at the same condition
Rahimi et al., 2014,
2018
Hepatocyte Three-step protocol – Serum free or FBS
medium with EGF, FGF2, DEX, ITS+1, NTA,
HGF, and OSM
ICC, RT- PCR, functional
assays
• Higher ALB, CYP7A1compared to bmMSC
• Express ALB and CK-18, secrete albumin
and produce glycogen similar to bmMSC
Khanjani et al.,
2014
Neural P4-8F with EGF and FGF2 then BDNF,
FBS, horse serum, N2 and all-trans- RA




• Similar ↑ NES, GFAP, but ↑ GFAP in
bmMSC
• Similar ↑ MAP2, GABABR1/2 and TUBB3
• ↑ K+, Ca2+, Na+ channel genes with EP
recording
• Similar ↑ TUBB3, NEUN, and GFAP to
bmMSC
• Secretion of BDNF in both MenSCs and
bmMSC
Azedi et al., 2017
Kozhukharova
et al., 2018
Glial lineage Two-step protocol via NSC: P4- 8F medium
with EGF and FGF-2 ATRA, FBS, horse
serum, N2 and rh-PDGF for glial cells
IF RT-PCR • Similar ↑ OLIG2 and NES in NSCs
• ↑ GFAP, OLIG2, MBP in glial-like cells
derived from both MenSCs and bmMSC
Azedi et al., 2014
5-aza, 5-Azacytidine; 8-Br-cAMP, 8-Bromoadenosine 3′,5′-cyclic adenosine monophosphate; ALB, Albumin; ALP, Alkaline phosphatase; ATRA, all-trans retinoic acid;
BDNF, brain-derived neurotrophic factor; FGF2, Basic Fibroblast Growth Factor; BGP, β-glycerophosphate; BMP6, Bone morphogenetic protein 6; bmMSC, Bone
Marrow derived mesenchymal stem cells; cAMP, Cyclic adenosine monophosphate; CK-18, cytokeratin 18; CYP7A1, cytochrome P450 7A1; dbcAMP, Dibutyryl Cyclic
Adenosine Monophosphate; Dex, Dexamethasone; E2, estrogen; EGF, Epidermal growth factor; EP, Electrophysiology; FCS, Fetal calf serum; FC, Flow cytometry;
GABABR, gamma aminobutyric acid type b receptor; GFAP, Glial Fibrillary Acidic Protein; GJA1, Gap junction alpha-1 protein; HGF, Hepatocyte growth factor; HPR,
human platelet releasate; IBMX, M3-isobutyl-1-methyl-xanthine; ICC, immunocytochemistry; IF, immunofluorescence; ITS+1, insulin–transferrin–selenium, linoleic-BSA;
MAP2, Micro-tubule-associated protein; MBP, Myelin basic protein; MenSCs, Menstrual blood-derived mesenchymal stromal cells; NES, Nestin; NEUN, Neuronal Nuclear
Protein; NSC, neurosphere-like cells; NTA, Nitrilotriacetic Acid; OCN, Osteocalcin; OSM, Oncostatin M; RA, Retinoic Acid; rh-PDGF, recombinant human platelet-derived
growth factor; RT-PCR, Reverse transcription polymerase chain reaction; sGAG, sulfated Glycosaminoglycan; TGFb3, Transforming growth factor b3; TNNT2, Cardiac
muscle troponin T.
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(CD117) marker resulted in high adipogenic differentiation
capacity (60–70%) (Patel et al., 2008), likely due to a more
homogeneous MSC population, although it is unknown
if CFU-F are also purified in the c-KIT+ subpopulation
of cultured MenSC.
Differentiation of MenSC into the chondrocytic lineage
has been demonstrated for CD117 purified cells in 2D
cultures yielding 45% positive cells, similar to bmMSC
(Patel et al., 2008). Unfractionated MenSCs cultured
in a 3D nanofibrous scaffold enhanced chondrogenic
commitment compared to a 2D culture system (Kazemnejad
et al., 2012), with extensive cartilage-like extracellular
matrix containing ∼50% more glycosaminoglycan than
control MenSCs differentiated in 2D. Chondrogenic
differentiation requires very low O2 tension, which is
better established in 3D compared to 2D cultures. MenSCs
produce high levels of Activin A, IGF-1, and FGF2, key
growth factors involved in chondrogenesis (Ren et al., 2016;
Uzieliene et al., 2018).
Co-culture of MenSC with murine cardiomyocytes generated
spontaneously beating human cells expressing cardiac specific
markers, indicating their differentiation into troponin
T-expressing cardiomyocytes (Hida et al., 2008). In vitro
cardiac differentiation of MenSC was compared with bmMSC
using two differentiation protocols and showed that continuous
FGF2 was superior to 5-aza-2′-deoxycytidine alone, as shown
by increased levels of late-stage cardiac markers (connexin
43 and Troponin T) (Table 3). This suggests that FGF2 has
a key role in differentiating cardiac cells from MSC sources.
MenSC had greater capacity than bmMSC to differentiate
toward cardiomyocytes regardless of the differentiation protocol
(Rahimi et al., 2014).
Collectively, the differentiation capability of unfractionated
MenSC isolated using conventional methods into two
mesodermal lineages (osteoblasts and adipocytes) is lower
than bmMSC isolated in a similar manner. This suggests
differences in tissue specific MSC properties likely reflecting
their tissue of origin. Purification of the rarer perivascular MSC
with specific markers appears to improve MenSC differentiation,
although c-KIT is not expressed on perivascular cells of human
endometrium in vivo (Figure 2), but whether induced in cultured
perivascular eMSC is unknown.
Endometrial stromal fibroblasts naturally differentiate into
decidualized stromal cells in vivo. Decidualization is mediated
by estrogen and progesterone, and supports the establishment
and continuation of pregnancy. MenSC have been differentiated
into decidual-like cells with 8-Br-cAMP and progesterone,
showing morphological changes and increased expression of
the decidualization markers prolactin and insulin-like growth
factor binding protein-1 (IGFBP-1), and attenuated expression
of MSC surface markers (Sugawara et al., 2014). Greater
secretion of these decidual proteins was observed for MenSC
compared to bmMSC and amnion MSC (Domnina et al.,
2016). It is possible that easily obtained MenSC could be
differentiated into decidual-like cells as a potential strategy
to mitigate infertility associated with insufficient endometrial
decidualization.
MenSC Differentiation Into Ectodermal
and Endodermal Lineages
Cultured MenSC transdifferentiate across lineage boundaries into
ectodermal (neurons and glia), and endodermal (hepatocyte)
lineages (Table 3). c-KIT sorted MenSCs express neuronal
phenotypic markers when grown in appropriately conditioned
medium (Borlongan et al., 2010). MenSC formed neurosphere-
like cells and then differentiated into neural and glial-like cells
comparable to bmMSC, and shown by increased expression of
classic neural markers (nestin, microtubule-associated protein 2,
gamma-aminobutyric acid type B receptor subunit 1 and 2, and
tubulin β3 class III) (Table 3) (Azedi et al., 2014, 2017).
Differentiation of MenSC into hepatocytes is dependent
on the concentrations of hepatocyte growth factor (HGF),
oncostatin M (OSM) and removal of serum from the induction
medium (Khanjani et al., 2015). Up-regulation of albumin
and CYP7A1 expression was higher in MenSC- compared to
bmMSC-derived hepatocyte-like cells, although cytokeratin-18
expression, albumin production and glycogen accumulation were
either lower or not different (Khanjani et al., 2014), indicating
similarity between MenSCs and bmMSC hepatocyte-like cell
differentiation potential.
Unfractionated MenSC have potential to differentiate into
keratinocyte-like cells, generating epidermal lineage markers via
co-culturing with keratinocytes derived from the foreskin of
healthy newborns (Faramarzi et al., 2016; Akhavan-Tavakoli
et al., 2017). MenSC were also induced to differentiate into
keratinocyte-like cells in 3D culture with human foreskin-
derived keratinocytes on a bilayer scaffold composed of amniotic
membrane and silk fibroin (Arasteh et al., 2018; Fard et al.,
2018). The MenSC-derived keratinocytes expressed keratinocyte-
specific markers K14, p63 and IVL (involucrin). Generating
keratinocytes from MenSC on an efficient natural construct has
potential applicability for MSC-based skin wound healing and
regeneration (Arasteh et al., 2018; Fard et al., 2018), although
these tissue engineering constructs have yet to be evaluated in an
animal skin wound repair model.
MenSC show considerable capacity to differentiate into
numerous lineages in vitro, although have lesser ability for several
bmMSC lineages. It would now be important to demonstrate the
potential of MenSC to undergo differentiation into these lineages
in vivo in animal models. Genomic sequencing (e.g., RNAseq)
would also shed light on how far down the various lineages
MenSC differentiate.
IMMUNOMODULATORY PROPERTIES
OF eMSC AND MenSC
Since the first report on the immunomodulatory properties of
MSC in 2002 (Bartholomew et al., 2002), numerous studies have
shown significant impact of MSC on key cells of the innate and
adaptive immune systems (Le Blanc and Mougiakakos, 2012;
Wang et al., 2014). These non-stem cell properties have been
exemplified in bmMSC (da Silva Meirelles et al., 2006). MSC
regulate monocyte infiltration to the site of injury, macrophage
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polarization and dendritic cell maturation (Jiang et al., 2005;
Kim and Hematti, 2009). MSC also inhibit NK cell proliferation
and target cell killing, and secrete IFN-γ (Sotiropoulou et al.,
2006). In the adaptive immune system, MSC suppress T cell
proliferation, shifting Th17 cells toward T regulatory cells
(Tregs) (Di Nicola et al., 2002; Sato et al., 2007). MSC also
impede B cell proliferation (Augello et al., 2005; Corcione
et al., 2006). Mechanism of interaction relies on direct cell-cell
contact and/or MSC secretion of immunosuppressive factors
including Indoleamine 2,3 deoxygenase (IDO), prostaglandin
E2 (PGE2), nitric oxide (NO), human leukocyte antigen G5
(HLA-G5), IL-10, IL-6 and TGF-β (Di Nicola et al., 2002;
Ren et al., 2010). MSC have also been used to successfully
treat patients with severe immune disorders, including Graft-
Versus-Host Disease (GVHD) and Crohn’s disease (Dalal
et al., 2012). This extensive literature indicates that MSC have
immunosuppressive rather than immunostimulatory functions.
Here we review the literature on the immunomodulatory
properties of eMSC and MenSCs.
In vitro Immunomodulatory Properties of
eMSC
The immunomodulatory properties of perivascular eMSC
have only recently been investigated. A transcriptional study
on CD140b+CD146+ eMSC revealed that perivascular eMSC
differentially expressed several immunomodulatory genes
compared to endometrial stromal fibroblasts (Spitzer et al.,
2012) (Table 4). A similar gene profile of differentially expressed
genes was observed between SUSD2+ perivascular eMSC
and SUSD2− stromal fibroblasts (Murakami et al., 2014)
(Table 4), including anti-inflammatory IL10. The gene profile
of perivascular eMSC treated and non-treated with the TGFβ
receptor (TGFβR) inhibitor, A83-01 to prevent apoptosis and
senescence during culture expansion, revealed upregulation
of many immune response genes in treated cells, including
interleukins (IL15, IL33, IL6ST), TNF and IFNγ related
genes, PGE2 synthesis genes (PLA2G4A, PTGS2/COX-2,
PTGES), and Toll-like receptors, TLR2 and TLR3 (Gurung
et al., 2018b). Together, these finding suggest that eMSC have
the ability to interact with the immune system in a similar
manner to bmMSC, exerting immunosuppressive functions
through paracrine mechanisms and by direct contact with
the target cell.
eMSC also influence T cell function by suppressing ConA-
stimulated murine T lymphocyte proliferation in a dose-
dependent manner (Yang et al., 2019). Blocking the TGFβR
in eMSC reversed the immunosuppressive effects of eMSC on
T cell proliferation, indicating a role for the TGFβ signaling
pathway. Of the various mechanisms assessed, neither IL-10,
PGE2, TGFβ or Tregs mediated the eMSC anti-proliferative
effects on T cells, however, IL-17A and Dickkopf-1 (DKK-1)
were secreted and may be candidates involved. Systemic eMSC
failed to inhibit swelling in a T cell-mediated mouse model
of skin inflammation, suggesting that eMSC have distinct
immunomodulatory properties that may not be sufficient to
restrain some T cell-mediated events (Yang et al., 2019).
eMSC Effects on Foreign Body Response to
Implanted Scaffolds in vivo
The immunomodulatory role of perivascular eMSC has been
explored in animal models of foreign body response to the
implanted biomaterials (Table 4). In a nude rat wound healing
model, human eMSC seeded on a gelatin-coated polyamide
mesh initially increased inflammatory M1 macrophages at
the mesh-tissue interface, followed by reduced inflammation
around the mesh filaments by switching macrophages from
an M1 to a wound healing M2 phenotype. Long term,
there were reduced CD68+macrophages at the mesh tissue
interface (Ulrich et al., 2014a). Human eMSC seeded on
the same polyamide/gelatin mesh inhibited secretion of the
inflammatory cytokines IL1β and TNF in early stages of
the host response, whereas induced gene expression of anti-
inflammatory M2 markers was observed later (Darzi et al.,
2018). These responses occurred earlier and were more marked
in the immunocompetent than immunocompromised mice.
This favorable immunosuppression by eMSC was confirmed
subsequently by eMSC-seeded degradable poly(L-lactic acid)-co-
poly(ε-caprolactone) (PLACL) nanofibers and 3D bio-printed
tissue engineering constructs in the same wound healing
immunocompetent mouse models (Mukherjee et al., 2019b;
Paul et al., 2019).
In vitro Immunomodulatory Properties of
MenSC
The immunomodulatory properties of MenSC have been also
been investigated, often in comparison with bmMSC. MenSC
effects have been mainly studied on T cell responses. In mixed
lymphocyte reactions (MLR), comprising MenSCs mixed with
allogenic human peripheral blood mononuclear cells (PBMCs),
cellular proliferation, IFN-γ and TNF levels were suppressed,
while IL-4 production increased (Murphy et al., 2008). The
MenSC suppressive effect on the allogenic MLR was dose-
dependent and biphasic, with a high MenSC:PBMC ratio
(1/2) suppressing PBMC proliferation and a low ratio (1/32)
supporting proliferation (Nikoo et al., 2012). MenSC effects
on cytokine levels were similarly concentration dependent with
reduced anti-inflammatory IL4+IL10+CD4+ T cells at low
MenSC:PBMC ratio compared to bmMSC (Luz-Crawford et al.,
2016). These effects suggest distinct immunosuppressive activity
of MenSC, similar to eMSC and appear less than bmMSC.
This may be due to more HLA-DR molecules on the MenSC
surface and fewer IFN-γ receptors, and that MenSC produce
less IDO, COX2, and Activin A (Luz-Crawford et al., 2016)
compared with bmMSC.
Pretreatment (licensing) of bmMSC with an inflammatory
stimulus enhances their immunosuppressive properties. In
contrast to the anti-proliferative effect of IFN-γ-pre-treated
bmMSC on CD4+ T cells, IFN-γ-IFN-g-pre-treated MenSC
show a milder response (Aleahmad et al., 2018). Untreated
MenSC cocultured with CD4+ T cells at ratios of 1:2–1:8
had a pro-inflammatory effect, increasing the proliferation of
anti-CD3/CD28-acitivated T cells, and IFN-γ pretreatment only
partially reduced this effect, suggesting that IFN-γ responsiveness





















TABLE 4 | Immunomodulatory properties of endometria MSC, stromal fibroblasts, and MenSC.
Cell type In vitro studies References Cell type In vivo studies References












• ↑ JAG1, TGFβ1, CXCR4, IL1RAP, IL1RL1
• ↔ IDO and PGE2
• ↑ CXCL1, CXCL10, CCL5, IL6, IL8
• ↓ IL33, AOC3, CCL7
eMSC and mouse splenocytes cocultured
• Dose dependently ↓ lymphocyte proliferation
• ↑ FOXP3 Treg in co-culture blocked by TGFβ inhibitor
• eMSC produced IL17 and DKK-1
• ↑ SOD3, SOD2, SOCS3, CXCL12, CXCL16, CCL8, IL-15, IL33,
IL6, TLR2/3, IL1R1, IL6R, TLR2, TLR3, PLA2G4A, COX2, PTGES,
C3, C2, CFB, CFD and CFI
• ↑ CCL2, GM-CSF, IGFBP-2, DKK-1 and EGF.
• Secrete IL6, IL8, MCP-1, MIF, MCP-3 and CXCL1.
Spitzer et al., 2012
Murakami et al.,
2014





Skin wound repair rodent models implanted with eMSC
seeded scaffolds
â Non-Degradable mesh- Rat
• M1 to M2 switch at 30 days
• ↓CD68+ MQ (90 days)
â Non-degradable – NSG and BL6 mice
• C57BL6: ↓ IL1β and TNFα secretion (3d). ↑Arg, MRC and
IL10 (3 and 7d).
• NSG: ↓ Arg (30d), MRC (14d). ↓TNFα (7 and 30d).
â Degradable Nanofiber – NSG mice
• ↑ Cellular infiltration around scaffold
• ↑M2 MQ and few M1 MQ (qualitatively)
• IL1β, TNFα, CCL2, CCL3,4,5,7,12,19 CXCL1,2,10 –CCR1,
CCR7 (1w), ↑ Arg1, Mrc1, IL6 and Il4ra (6w).
â 3D printed mesh – NSG mice
• ↑ M2 MQ and ↓ M1 MQ within implanted biomaterial (1w).
Ulrich et al., 2014a









IFN and TNF stimulated ESC for 3 and 7 days
• Express IFN-γ1 and TNF I/II receptors
• ↑ expression: HLA-I but not HLA-II
• IDO, IL6 and PGE2 production






â EAE in BL6 mouse
• ↓ EAE score
• ↓ MN, TH1 and TH17 in CNS
• ↑ IL10, IL27 and IDO in mouse splenocytes
Peron et al., 2012
Menstrual blood stem cells
Plastic adherent
MenSC
Proliferation of allogenic PBMCs in MLR
• ↓ proliferation at 1:1 and 1:10 (MenSC: PBMC), with higher
inhibition at 1:1.
Proliferation of allogenic PBMCs in MLR
• ↓ proliferation at high MenSC concentrations (1:1 or 1:2;
MenSC:PBMC ratios)
• ↑ proliferation at low MenSC concentrations (1:32 or 1:64;
MenSC:PBMC ratios)
Mo differentiation and maturation
• Interfere with Mo ↑ immature DC: ↓CD80, 86, HLA-DR on DCs.
• Interfere early stages DC maturation: ↓ CD14, CD1a on DCs.
• ↑IL6 and IL10 in co-culture with Mo.
IL2 supplemented NK cells co-culture with IL1β, IFN ± pre-treated
MenSCs
• Untreated MenSCs dose dependently ↑ NK cell proliferation
• Treated MenSCs ↓ NK cells proliferation.
• ↓ NK cell cytotoxicity, GzmA, GzmB and perforin.
PHA-activated PBMC ± IFNγ and IL1β pre-treated MenSCs.
• ↓ proliferation at both 1:10 and 1:100 MenSC:PBMC ratios
• ↓ %CD4/CD8+ IFNγ+ cells
• ↓ %Th17 cells at 1:10 but not in 1:100 MenSC:PBMC ratio
Wang et al., 2012
Nikoo et al., 2012
Bozorgmehr et al.,
2014






â DSS induced colitis in BL6 mouse
• ↓ intra-colon IL-2 and TNF-α, ↑ IL-4, IL-10.
• ↓ MHC-II expression in splenic DCs.
• ↓CD3+CD25+ and CD3+CD8+T cells, and ↑
CD4+CD25+Foxp3+ Tregs.
â Anti- PD-L1 ± pre-treated MenSCs in DSS induced
colitis in mouse.
• ↓ infiltration of immune cells.
• ↓ TNFα and IFNγ in serum and colon.
• ↓ CD4 and CD8 T cells in colon.
• ↓CD11c+MHC-II+ DC in spleen, total MQ but ↑ M2 MQ.
• ↑CD206 cells and CD4+CD25+ FOXP3 Treg.
â DSS induced colitis in mouse.
• ↓ immature splenic plasma cells and deposition of IgG in
the colon.
• ↑regulatory B cells and IL10.
â CIA and GVHD in mice
• CIA model: ↑ TNF and IL6
• GVHD: ↑ CD45 cells in the spleen
â Allograft heart transplantation in mouse
• ↓ IgG and IgM production, and B cells activation.
Cabezas et al.,
2014
Shi et al., 2019
Xu et al., 2018
Luz-Crawford et al.,
2016
Xu et al., 2017
CIA, collagen-induced arthritis; Dec, decidualised; DSS, dextran sodium sulfate; EAE, Experimental Autoimmune Encephalomyelitis; FOXP3, Forkhead box 3; Gzm, Granzyme; GVHD, Graft versus host disease; HLA,
Human leukocyte antigen; IDO, indole-amin-2, 3 dioxygenase; IFN-γ, Interferone-γ; Ig, Immunoglobulin; IL, Interleukine; MES, Melt electrospinning; MHC-II, Major histocompability antigen class-II; MLR, Mixed leukocyte
reaction; Mo, Monocyte; MQ, Macrophage; NK, Natura killer; PBMC, Peripheral blood mononuclear cell; PD-L1, Programmed death-ligand 1; PGE 2, Prostaglandin E2; PHA, Phytohemaglutinin; Th, T helper; TNF-α,
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of MenSC is comparatively lower than bmMSC (Figure 3)
(Aleahmad et al., 2018). The impact of MenSC on human
T cell proliferation in vitro is complex and depends on
the cytokine milieu, T cell stimulating factors, MenSC/T cell
ratio and the co-culture system. MenSC have a weaker and
distinct in vitro effect on T cell proliferation compared to
bmMSC (Aleahmad et al., 2018), possibly similar to the lesser
characterized eMSC responses.
As expected, MenSC also have an impact on the innate
immune system, including human blood monocyte-derived
dendritic cells (MoDCs) (Table 4) (Bozorgmehr et al., 2014),
NK cells and tissue macrophages. MenSC co-cultured with
human monocytes interfered with MoDC differentiation at the
phenotypic level. The immature DCs expressed suboptimal co-
stimulatory molecules and had low levels of CD40, CD80, CD83
and CD86. MenSC secreted IL-6 and IL-10 (Bozorgmehr et al.,
2014), which typically inhibit monocyte to DC differentiation
(Allavena et al., 1998; Chomarat et al., 2000). Uterine NK
(uNK) cells constitute the main component of the endometrial
innate immune system, comprising 50–70% of lymphoid cells
in early pregnant endometrium (Moffett-King, 2002). uNK cells
function in maintaining a successful pregnancy by preventing
allorejection of the embryo and regulating vascular remodeling
(Hanna et al., 2006; Kalkunte et al., 2009). Dysregulation of
uNK cell function may be involved in the pathogenesis of
recurrent pregnancy loss (Dosiou and Giudice, 2005) indicating
the importance of tightly regulating uNK cell cytotoxic function.
Unstimulated MenSCs induced NK cell proliferation partly due
to lower production of IGFBPs 1-4 compared to bmMSC.
However, in a pro-inflammatory milieu involving IFN-γ/IL-1β,
MenSCs substantially inhibited NK cell proliferation through
production of IL-6 and TGF-β (Shokri et al., 2019). IFN-
γ/IL-1β-stimulated MenSC also curbed NK cell cytotoxicity by
decreasing granzyme A, granzyme B, and perforin expression.
FIGURE 3 | Properties of MenSCs in vitro and in vivo. (A) Similar to their well-known counterparts (bmMSC), MenSCs have the ability to differentiate to cells of
different lineages and express typical MSC-associated markers. (B) Impact of MenSCs on the adaptive and innate immune systems. MenSCs secrete IL-6 and IL-10
that inhibit optimal maturation of human monocyte-derived dendritic cells (DC). MenSCs shift macrophages toward the M2 (anti-inflammatory) profile. MenSCs either
inhibit or support T cell proliferation depending on MenSC/T cell (PBMC) ratio. MenSCs increase Treg frequency, decrease the number of TH17 and IFNγ+
CD4+/CD8+ T cells and cytotoxic capacity of NK cells. MenSCs decrease antigen-specific antibody secretion and proliferation of B cells. (C) Utilization of MenSCs
in preclinical settings ranges from immune-mediate disorders: arthritis and GVHD to regenerative and reparative applications: cardio protection, liver and lung fibrosis
and neuroprotection.
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NK cells also killed MenSC in a MHC- and time-dependent
manner. These results suggest a critical role for MenSC in
endometrial tissue homeostasis and induction of a pregnancy-
friendly phenotype in decidual NK cells.
MenSC Immunomodulatory Effects in vivo
Recently it was shown that MenSC influence the humoral
immune responses in a mouse model of heart transplantation
by attenuating antibody responses (Xu et al., 2017). MenSC
injection 24 h following allograft heart transplantation
prolonged graft survival in recipient mice by rapidly reducing
intragraft deposition of donor-specific IgG and IgM antibodies
and reducing donor-specific antibody secreting B cells.
It remains to be investigated whether MenSC ameliorate
autoantibody production in patients with antibody-mediated
autoimmune diseases.
In a murine model of colitis, intravenous MenSC injected 2–
8 days after disease induction (Cabezas et al., 2014) increased
intra-colon IL-4 and IL-10 and decreased IL-2 and TNF,
and splenic dendritic cells expressed lower levels of MHC-II
compared to untreated controls (Cabezas et al., 2014). The
percentage of CD3+CD25+ and CD3+CD8+ T cells was reduced
and Tregs increased. MenSC also promoted F4/80+CD206+
M2 macrophage migration and reduced IgG deposition in
the injured colon, decreased splenic plasma cells, increased
regulatory B cells (Xu et al., 2018), and appeared to mediate these
immunomodulatory effects via PD-L1 (Shi et al., 2019).
Not all studies have corroborated the immunomodulatory
effects of MenSC in disease models. MenSC failed to switch
T cell-related immune responses toward an anti-inflammatory
direction in a murine model of arthritis (Luz-Crawford et al.,
2016) (Table 5). MenSC injection increased splenic TNF levels
and did not reduce lymph node pro-inflammatory Th17 cells
and in contrast, bmMSC did not exert any beneficial impacts on
disease progression. MenSC injection into a humanized GVHD
mouse model, where irradiated NOD-SCID mice received human
PBMC, has been efficacious in reducing disease severity (Luz-
Crawford et al., 2016). In this acute inflammatory model, intra-
peritoneal MenSC were superior to bmMSC, in contrast to
the arthritis model. MenSC improved intestine structure and
survival rate. However, immunosuppressive functions were not
observed for MenSC, but rather their effect was attributed to their
regenerative capacity. MenSCs expressed high levels of VEGF
and FGF2, and induced greater vascularization compared with
bmMSC. MenSC also had a greater migratory capacity to target
organs due to their higher expression of surface CXCR4.
MenSC also have anti-microbial activity. In a cecal ligation
and puncture mouse model of sepsis, the combination of MenSC
and antibiotic improved the survival rate of affected animals
(up to 95%) compared with control animals receiving either
treatment alone. The MenSC/antibiotic combination increased
bacterial clearance from blood, and reduced the inflammatory
cytokines IL-8, TNF, and MCP in peritoneal fluid, without loss
of T and B lymphocytes (Alcayaga-Miranda et al., 2015b).
Taken together, eMSC and MenSC have a range of effects
on both arms of the innate and specific immune responses
(Figure 3), however, the discrepancies between in vitro
and in vivo findings and considerable variation between
experimental models necessitate further investigation to identify
the underlying mechanisms that orchestrate the cross-talk
that MenSC and eMSC utilize to modulate the immune
system. Standardization of key variables of human disease and
disease models including immune versus non-immune nature
of the disease, local versus systemic administration of cells,
chronic versus acute disease, and the dose and timing of
injected MenSC as well as MSC cell type (perivascular versus
unfractionated stromal fibroblast populations) and experimental
models as has been promulgated for bmMSC will further increase
understanding of the distinct properties of eMSC and MenSC.
THERAPEUTIC POTENTIAL OF eMSC
AND MenSC
Challenges for MSC-Based Therapies in
Regenerative Medicine
Hundreds of clinical trials of various MSC have overall shown
underwhelming results in regenerative medicine applications
(Prockop et al., 2014). This is due in part to the use of preclinical
mouse studies using syngeneic mice, MHC-matched cells and
achievable dosing (Galipeau and Sensebe, 2018). Large animal
preclinical models are particularly important to trial MSC before
going to the clinic to resolve these issues. To date long term
engraftment of substantial numbers of infused MSC has not
been demonstrated, rather only a small population (2–10%)
remain in the days following administration (Dimmeler et al.,
2014). Allogeneic MSC will be rapidly removed by the innate
immune system, and while autologous cells may prevail, few
appear to integrate into tissues. This lack of MSC integration
is due to the ischemic or inflammatory environment of the
diseased tissue/organ and loss of vascular niches which may
be replaced with fibrosis. Aged tissues and chronic disease can
also hinder MSC integration (Dimmeler et al., 2014). Despite
these challenges, MSC can have dramatic effects through their
paracrine actions, appearing to reset the innate immune system
and promoting endogenous cellular repair without substantial
integration (Caplan, 2016).
eMSC in Regenerative or Reparative
Medicine
Since perivascular eMSC originate from a cyclically regenerating
tissue with accompanying angiogenesis (Gargett and Rogers,
2001) they are excellent candidates with therapeutic potential
for tissue repair and possibly tissue regeneration. Their pericyte
and perivascular identity indicate their specific roles in regulating
angiogenesis, inflammation and fibrosis (Thomas et al., 2017),
suggesting eMSC are a good candidate for regenerative or
reparative medicine.
Endometrium and Decidua Regeneration
As mentioned above, human eMSC differentiate into decidual
cells. This property has been harnessed for generating a
tissue engineered uterus through repopulating decellularized
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extracellular matrix (ECM) constructs with cells, including
endometrial stromal fibroblasts (Fu et al., 2014; Hellstrom
et al., 2017; Tiemann et al., 2020). This bioengineering
approach has been conducted in decellularized uterus from
rat (Miyazaki and Maruyama, 2014; Hellstrom et al., 2016;
Kuramoto et al., 2018), pig (Campo et al., 2017) and human
(Olalekan et al., 2017). Allogeneic endometrial stromal cells
and bmMSC seeded into decellularized rat uteri diffused
TABLE 5 | Preclinical and clinical applications of endometrial MSC and Menstrual blood stromal cells.
Disease Animal model Findings References
Perivascular endometrial mesenchymal stem/stromal cells
Pelvic organ prolapse • Multiparous sheep, vaginally implanted autologous
ovine eMSC seeded PA/G and PA mesh
• Rat, SC implantation of DiO-eMSC seeded on PA/G
• Mouse, SC implantation of bio-printed eMSC on 3D
printed scaffold
• NSG mouse, implantation of eMSC seeded degradable
electrospun nanofiber.
• 30 days eMSC survival, ↓ myofibroblast, ↑ elastin, ↓
CD45+ leukocytes
• ↑ neovascularization (7d), ↓ mesh/tissue stiffness,
crimped collagen deposition
• Better tissue integration, collagen deposition
• Better tissue integration, ↑Cellular infiltration into mesh
Emmerson et al., 2019
Ulrich et al., 2014a
Paul et al., 2019
Mukherjee et al., 2019b
Parkinson disease • Mouse, immunodeficient and immunocompetent MPTP
lesions
• Migrated and differentiated to lesion, ↑ striatal
dopamine and its metabolites
Wolff et al., 2011
Endometrial stromal/stem cells (ESC)
Diabetes mellitus • Immunocompromised mouse Type I diabetes.
• ESC differentiated to pancreatic β-like cells were
injected into kidney capsule
• Insulin production in single cells from kidney capsule
• minimized diabetes-associated complications
• reduced blood glucose
• prolonged survival of mice
Santamaria et al., 2011
Li et al., 2010
Menstrual blood stromal/stem cells (MenSCs)
Myocardial infarction • Nude rat, GFP labeled MenSCs injected into the center
and margin of infarcted area
• Rat, intracardial injection
• Ameliorated left ventricular systolic function
• Trans-differentiation to cardiomyocytes
• ↓ fibrotic areas
• Improved cardiac function
• trans-differentiation to cardiomyocytes
• ↑ Akt, Erk1/2, Stat3, proliferation and c-kit+
• ↓ apoptosis and p38 signaling
Hida et al., 2008
Jiang et al., 2013
Critical limb ischemia • BALB/c mice, MenSCs injected into hind-limb of CLI
mice
• no muscle necrosis in damaged area Murphy et al., 2008
Acute liver failure (AFL)
Liver fibrosis
• BALB/c mouse, IV injection of GFP labeled MenSCs
• ICR mouse, IV injection of GFP labeled MenSCs
• ↑ Liver regeneration, donor cells homed to injured area,
↓ Ast, Alt, urea and total bilirubin
• ↑ hepatic markers Alb, Ck18 and Tat
• donor cells migrated to injury




Chen et al., 2017b
Premature ovarian
failure
• C57BL6 Mouse, tail-vein injection of DiO labeled
MenSCs Premature ovarian failure models
• C57BL6 Mouse, IV injection of MenSCs
• ↑ Amh, Fshr, Ki67, ovarian weight, Plasma E2 levels
and normal follicles
• ↓ apoptosis, restored ovarian function and normalized
serum ovarian hormones.
Liu et al., 2014;
Manshadi et al., 2019
Feng et al., 2019
Poor ovarian response • POR women, IO injection of MenSCs • ↑ fertilization rate
• ↑ pregnancy rate
Zafardoust et al., 2020
Acute lung injury • C57BL6 mouse, IV injection of MenSCs
• LPS-induced injury
• ICR mouse, IV injection of MenSCs
• ↑ pulmonary microvascular permeability, expression of
Pcna, Kgf and Il-10
• ↓ histopathological damage, Il-1b expression and
Caspase-3 protein expression
• ↓ inflammatory response and ↑lung tissue repair
Xiang et al., 2017
Ren et al., 2018
Pulmonary fibrosis • C57BL6 mouse, tail-vein injection of MenSCs
bleomycin model
• ↓ collagen production, deposition, and wet/dry lung
weight
Zhao et al., 2018b
Excisional wound
defect
• C57BL6 mouse, intradermal injection of PKH2- labeled
MenSCs
• Rat, Implantation of amnion seeded with MenSCs
• ↑ wound closure, Neovascularization and mature
vasculature, collagen content and VEGF
• improved wound closure
Cuenca et al., 2018
Farzamfar et al., 2018
Intrauterine adhesion • ICR mouse, IV injection of DIL labeled MenSCs • ↑ endometrial thickness and microvessel density
• ↑ conception rate and embryo number
Zhang et al., 2016
Asherman’s syndrome • Infertile women with severe AS, transvaginal delivery of
autologous MenSCS
• ↑ endometrial thickness
• 2/5 conceived and 1/5 spontaneous pregnancy
Tan et al., 2016
OGD stroke • Rat, IC and IV injection of MenSCs Neuroprotection
model
• ↓ behavioral and histological impairments Borlongan et al., 2010
(Continued)
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TABLE 5 | Continued
Disease Animal model Findings References
Sciatic nerve defect • Rat, MenSCs seeded neural guidance conduit
implanted into nerve defect area
• Improved sciatic functional index
• Prevented muscle weight- loss
• ↓ HPLT in MenSCs-seeded conduit group
Farzamfar et al.,
2017
Alzheimer’s disease • Appswe/PSEN1-overexpressed dE9 mouse
• IT injection of MenSCs into hippocampus
• Improved spatial learning and memory
• ↓ plaques and hyperphosphorylation
• ↑ several Aβ degrading enzymes
Zhao et al., 2018a
Diabetes mellitus • Mouse type I diabetes, IV injection of MenSCs model of
how mice was made diabetic
• ↑ insulin production, normalized glucose level
• ↓Weight loss, prolonged life-span
• Recovered islet structure
Wu et al., 2014
Aβ, Amyloid beta; Alb, Albumin; Alt, Alanine aminotransferase; Amh, Anti-Müllerian hormone; AS, Asherman’s syndrome; Ast, Aspartate transaminase; CD, Cluster of
differentiation; CK, Cytokeratin; CLI, Critical limb ischemia; DiO, 3,3′-dioctadecyloxacarbocyanine perchlorate; E2, Estradiol; Fshr, Follicle stimulating hormone receptor;
GFP, Green fluorescent protein; HPL, Hot plate latency; IC, Intracerebral; ICR, Imprinting control region; Il, Interleukin; IO, Intraovarian; IT, intrathecal; IV, Intravenous;
KGF, Keratinocyte growth factor;, LPS, Lipopolysaccharide; MPTP, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; NSG, NOD scid gamma mouse; OGD, Oxygen glucose
deprivation; PA/G, Gelatin coated polyamide; Pcna, Proliferating cell nuclear antigen; POR, Poor ovarian responder; SC, Subcutaneous; TAT, Tyrosine aminotransferase,
VEGF, Vascular endothelial growth factor.
into the matrix and expressed the stromal marker vimentin
and endothelial marker CD31, demarcated by cytokeratin
expressing epithelial cells (Miyazaki and Maruyama, 2014).
Transplantation of these uterine constructs into partially
excised uteri, regenerated endometrial tissue which differentiated
into desmin-expressing decidual-cells and achieved pregnancies
(Miyazaki and Maruyama, 2014). There was evidence of fetal
development, however, no evidence of placentation at the graft
site. In another approach to reconstitute native, functional
endometrium, a rat GFP+ endometrial epithelial cell-sheet was
layered on two layers of adherent GFP+ endometrial stroma
cell-sheets and transplanted into a full thickness endometrial
defect in a rat model (Kuramoto et al., 2018). Full thickness
endometrium with luminal and glandular epithelium and
stromal compartments was generated and pregnancy established
on the regenerated endometrium with placentation and fetal
heart movements detected. Preliminary results using similar
approaches in a larger pig model have commenced (Campo
et al., 2017). Using human endometrial Side Population cells
including stromal cells demonstrated integration of vimentin+
and cytokeratin+ cells in the decellularized pig uterus. In an
in vitro model, endometrial stromal cells, which likely contained
a small population of eMSC, repopulated decellularized human
endometrial substrates and proliferated in the scaffold (Olalekan
et al., 2017). Most importantly, the cells underwent decidual
changes upon stimulation with an estrogen and progesterone
treatment protocol mimicking the human 28-day menstrual
cycle. The infiltrated cells expressed estrogen and progesterone
receptors, and secreted prolactin and IGFBP-1, markers of
decidualization. These recent approaches indicate the feasibility
of using eMSC and endometrial stromal fibroblasts as cell sources
for regenerative medicine in uterine biology.
Pelvic Organ Prolapse
The potential of eMSC in regenerative or reparative medicine
has been explored for a common women’s gynecological disorder,
pelvic organ prolapse (Ulrich et al., 2013; Emmerson and Gargett,
2016; Gargett et al., 2019; Mukherjee et al., 2019a). An autologous
approach has been investigated and tissue engineering constructs
comprising eMSC and novel non-degradable mesh (Ulrich et al.,
2012), degradable nanofiber mesh (Mukherjee et al., 2019b), and
3D bioprinted mesh/eMSC (Paul et al., 2019) have been explored
in both rodent and large animal ovine models (Emmerson et al.,
2019). In these studies, xenogeneic human eMSC delivered on
a mesh in a model of subcutaneous wound repair, exerted
a paracrine effect. DiO- or mCherry lentiviral-labeled eMSC
implanted on a non-degradable polyamide/gelatin composite
mesh, were detectable for 1–2 weeks in immunocompromised
rats and mice (Ulrich et al., 2014a; Darzi et al., 2018) and up
to 3 days in immune intact mice (Darzi et al., 2018). Despite
this, the eMSC exerted marked paracrine effects, promoting
early neovascularization, an anti-inflammatory response and
supporting the deposition of physiological, crimped collagen
rather than scar (Edwards et al., 2015). These changes induced
by eMSC resulted in a clinically relevant outcome, a reduction
in the stiffness of the mesh/tissue complex in the long term
(90 days) (Ulrich et al., 2014a). In studies using degradable
PLACL nanofiber/gelatin (Mukherjee et al., 2019b) or 3D printed
PCL scaffolds (Paul et al., 2019), m-Cherry-labeled eMSC again
reduced the foreign body response, slowed mesh degradation
and induced endogenous cell influx into the scaffold in vivo,
thereby promoting tissue repair. These are outcomes of clinically
desired responses, particularly for application in pelvic organ
prolapse repair surgery.
To more accurately model the translational approach to be
used clinically, autologous, adventitial perivascular ovine eMSC
(Table 2), labeled with paramagnetic nanoparticles conjugated to
FITC were surgically delivered with non-degradable polyamide
mesh in an ovine model of vaginal repair (Emmerson et al.,
2019). A two-step procedure was required, firstly implanting the
mesh followed by separate delivery of the eMSC in a collagen
gel onto the mesh and crosslinking with blue light in situ,
followed by suturing. Approximately 10–20% of the autologous
eMSC survived 30 days following implantation. As observed
in the rodent models, the eMSC modulated the inflammatory
response and reduced myofibroblast accumulation around mesh
filaments. Important lessons were learnt using this large animal
model, particularly related to the separate delivery of eMSC and
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mesh. This modification to our protocol prevented one of the
major adverse events associated with transvaginal mesh use, mesh
exposure, that had resulted in the banning of polypropylene
vaginal mesh by the FDA. This could not have been predicted
from using mouse models of skin wound repair and shows
the importance of closely recapitulating the clinical condition
in large animal models before clinical translation of an MSC-
based therapy.
Other Reparative Applications of eMSC
Human and monkey endometrial stromal fibroblasts
transdifferentiated into cells with morphological, chemical
and electrical activity of dopaminergic neurons have been
investigated in several animal models. They engrafted and
migrated to site of lesion in chemically induced mouse and green
monkey (Table 2) models of Parkinson disease, differentiated
to neuronal-like cells resulting in increased striatal dopamine
and dopamine metabolite concentrations (Wolff et al., 2011,
2015). However, further studies on clinical outcomes such as
the behavioral studies are warranted. Type 1 diabetes mellitus
is a clinical condition which can benefit from islet-based cell
transplantation. The plasticity of human endometrial stromal
fibroblasts has been utilized to generate insulin secreting cells.
These differentiated cells produced human insulin, decreased
blood glucose levels and minimized diabetes-associated
complications such as weight loss, dehydration, cataracts,
delayed wound healing and sedative behavior in a mouse model
of diabetes mellitus (Li et al., 2010; Santamaria et al., 2011). These
differentiated cells were more efficient in a 3D construct, and
were resistant to oxidative stress, normalized glucose levels and
prolonged survival of the recipient mice (Li et al., 2010).
Both eMSC and endometrial fibroblasts show potential
in regenerative and reparative medicine, with early studies
suggesting capability in tissue engineering approaches using
decellularized tissues or biomaterial scaffolds to deliver the cells
to tissues requiring regeneration. Mode of action may be both
cellular integration and paracrine.
MenSC in Regenerative or Reparative
Medicine
MenSC are also an attractive cell source with potential for clinical
application. MenSC have been assessed in various preclinical
animal models of disease and in regenerative and reparative
medicine (Table 5). Here, we will briefly review these studies.
Cardio-Reparative Potential
One of the first studies proposing the prospective use of MenSC
differentiation in the clinical setting assessed the ability of
MenSC to improve cardiac function after myocardial infarction.
MenSC transplanted into a rat model ameliorated left ventricular
systolic function and diminished fibrotic areas (Hida et al., 2008).
In vivo differentiation of MenSC to cardiomyocytes in infarcted
areas was demonstrated in the absence of recipient and donor
cell fusion. Similar outcomes were obtained following MenSC
injection into the ischemic zones of an immunocompetent rat
model of myocardial infarction (Jiang et al., 2013). The therapy
resulted in significant preservation of myocardial viability in
the infarct zone and improvement in cardiac function, effects
mostly attributed to the paracrine activity of MenSCs rather than
transdifferentiation to myocardial cells.
Hepato-Reparative Potential
MenSC’s ability to differentiate toward hepatic cells in vitro
(Khanjani et al., 2015) raised the possibility of MenSC application
for treating liver disorders. Both MenSC and bmMSC, with
the capacity to differentiate toward hepatocytes, prolonged the
survival of mice with acute liver failure. MenSC localized in
the damaged liver within 2 h following transplantation. This
treatment also improved liver histology and architecture within
weeks after MenSC injection. The MenSC therapy reduced
serum levels of liver enzymes and metabolites (AST, ALT, urea,
and total bilirubin) in the mice. Reduced hepatic degeneration,
inflammatory cell infiltrate and collagen fiber deposition and
improved glycogen storage were observed following MenSC
administration (Fathi-Kazerooni et al., 2017), indicating the
protective and reparative role of MenSC in acute liver damage.
It is likely that MenSC improvement of liver function is due
to paracrine activity rather than differentiating into hepatocyte-
like cells in improving liver fibrosis. In a murine model
(Chen et al., 2017b), few MenSC differentiated into hepatocyte-
like cells, suggesting the complexity of the in vivo milieu
influencing MenSC differentiation. MenSC migrated to the
fibrotic area, reduced already deposited collagen and significantly
improved liver function. Nevertheless, end-stage liver fibrosis
with few healthy hepatocytes may be a poor environment
for survival of MenSC that also diminishes their ability to
potentially differentiate into hepatocyte-like cells. This questions
the utility of MenSC as a therapeutic modality to patients
with cirrhosis. Further investigation in first reducing fibrosis in
cirrhosis using MenSCs before attempting to regenerate hepatic
tissue is warranted.
Ovarian Function and Reserve
The reparative capacities of MenSCs was exploited to treat
premature ovarian failure (POF) in mouse/rat models (Liu
et al., 2014; Feng et al., 2019; Manshadi et al., 2019; Yan
et al., 2019). Intra-ovarian or intravenous injection of MenSCs
reduced apoptosis and restored ovarian function, shown by
expression of the ovarian markers, follicle-stimulating hormone
receptor (Fshr), inhibin α/β, anti-Müllerian hormone (Amh),
Ddx4 and Vegfa, and rising plasma levels of the ovarian
hormones, estrogen and progesterone. Increased numbers of
primary, mature and total ovarian follicle numbers were
observed. DiI-labeled MenSC localized to GCs of immature
ovarian follicles (Manshadi et al., 2019). Microarray analysis
revealed greater similarity between mRNA expression patterns
in the ovarian cells posttransplantation and human ovarian
tissue than the pre-transplantation pattern in MenSCs, suggesting
transdifferentiation into ovarian cells or fusion of MenSCs
with murine cells (Liu et al., 2014). More importantly, mated
mice grafted with MenSCs had more live births indicating the
potential of MenSC to repair ovarian function (Feng et al., 2019).
Mechanistic analyses revealed that mice treated with MenSCs
improved ovarian microenvironment homeostasis through
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regulation of the ECM-dependent FAK/AKT signaling pathway
(Feng et al., 2019). Similarly, in vitro, MenSC increased indices
of mouse follicular growth, including survival rate, diameter and
antrum formation, Bmp15 and Gdf9 expression and maturation
rate in a 3D culture system. Secreted progesterone and estradiol
increased in co-cultured murine preantral follicles and human
MenSC implying a supportive role of MenSCs in follicle
development, growth and maturation (Rajabi et al., 2018). In
a recent clinical trial in 15 women, intraovarian injection of
autologous MenSC in poor ovarian responders increased clinical
pregnancy and live births (Zafardoust et al., 2020).
Collectively, MenSC impact on ovarian follicle development
through paracrine signaling and potentially transdifferentiation
highlights the possible utility of MenSC for ovarian function
restoration in patients with POI and also fertility preservation
approaches using in vitro follicle maturation. These pre-clinical
findings and an early phase clinical trial warrant further
investigation of the efficacy of MenSC for treatment of POI.
Lung Injury
MenSCs have been used to treat LPS-induced acute lung injury in
a murine model (Xiang et al., 2017). Intravenously administered
MenSC localized to the injured area and demonstrated repair
of lung tissue morphology, improved lung microvascular
permeability, and reduced clinical symptoms. MenSC exerted
an anti-inflammatory effect, reducing lung inflammatory cells
and IL-1β, whereas IL-10 was increased in both lung tissue and
broncho-alveolar lavage fluid. Keratinocyte growth factor, which
plays a major part in repair of damaged lung was increased, and
together with decreased caspase-3 expression further supported
the protective impact of the infused MenSC. It is likely that the
reparative effect of MenSC can be ascribed to cell-cell contact
and/or their paracrine function. Similarly, MenSC injection
improved acute lung injury scores through normalization
of lung O2 pressure. MenSC reduced neutrophil frequency,
myeloperoxidase activity, and pro-inflammatory cytokines levels
in bronchoalveolar fluid (Ren et al., 2018). MenSC injection
also reduced inflammation and collagen deposition in a mouse
model of bleomycin-induced pulmonary fibrosis (Zhao et al.,
2018b). In summary, in acute lung injury and pulmonary fibrosis
models, MenSC suppressed innate immune cells, lowered pro-
inflammatory cytokines and increased IL-10 in lung, and lung
function and morphology were restored, effects likely mediated
by paracrine mechanisms.
Skin Wound Repair
The reparative potential of MenSCs in a murine excisional wound
splinting model (Cuenca et al., 2018) showed that intradermal
injection of MenSCs into a persistent wound improved healing
and increased angiogenesis. Two pro-angiogenic genes, Il-8
and Vegf were upregulated in the wounds and there was
maturation of wound vasculature. The MenSC-injected group
also showed high density, and well-organized collagen fibers,
suggesting MenSC have potential application for wound healing
and cutaneous regeneration. MenSC seeded on an amniotic
membrane improved wound closure in a rat excisional wound
defect model (Farzamfar et al., 2018). In vitro, MenSCs
differentiated into keratinocyte-like cells (Akhavan-Tavakoli
et al., 2017), an effect potentiated in 3D culture (Fard et al.,
2018) or in a biomimetic nanofibrous scaffold, two approaches
that increased the wound healing capacity of MenSC (Arasteh
et al., 2018). Such data imply the importance of ECM in the
differentiation of MenSC into keratinocyte-like cells and further
highlight the value of MenSCs as a potential therapeutic in
clinical settings.
Intrauterine Adhesions and Endometrial
Decidualization
The reparative potential of MenSC has been explored in a
mouse model of endometrial injury and intrauterine adhesion
(Zhang et al., 2016), where the endometrium is partially replaced
by fibrotic scar tissue (Gargett and Ye, 2012). Intravascular
injection of MenSCs rapidly repaired the injury by increasing
microvessel density, resulting in increased endometrial thickness.
Fertility was restored with a higher conception rate and larger
numbers of implanted embryos compared to untreated controls.
MenSC-conditioned medium promoted angiogenesis in vitro
by activating Akt and Erk pathways and overexpression of
genes involved in angiogenesis. Autologous cultured MenSCs
administered to 7 women with severe Asherman’s syndrome,
where intrauterine adhesions have replaced the endometrium,
increased endometrial thickness to 7 mm in five of seven
patients (Tan et al., 2016). Of the four patients who had
undergone embryo transfer, two conceived and one had
a spontaneous pregnancy, suggesting that MenSC reduced
fibrosis and promoted functional endometrial repair of the
injured endometrium.
Neuroprotective Potential
The application of MenSC, which can differentiate toward
glia and neural cells in vitro (Table 3), for neuroprotection
is an emerging research area. In an adult rat stroke model,
intracerebral or intravenous MenSC transplantation ameliorated
motor and behavioral symptoms and diminished neuronal
cell death (Borlongan et al., 2010). Implantation of MenSC-
seeded gelatin-based scaffolds in rats with sciatic nerve defect
improved sciatic nerve function and reduced and gastrocnemius
muscle loss to a similar level as bridging the nerve defect
with autologous resected nerve segment (Farzamfar et al.,
2017). MenSC also improved cognition function and memory
defects in a mouse APP/PS1 model of Alzheimer’s disease
(Zhao et al., 2018a). In the hippocampus, more activated
microglia were observed which had altered function as less
TNF and IL-1β were produced. These activated microglia had
higher expression of insulin degrading enzyme and neprilysin,
proteases responsible for Aβ plaque degradation. These results
highlight the potential of MenSC in improvement of the
pathological and cognitive defects in pre-clinical models of
Alzheimer disease.
Other Potential Reparative Applications of MenSC
The regenerative ability of MenSC to promote muscle
regeneration was demonstrated in a murine Mdx model
of Duchenne muscular dystrophy, where skeletal muscles
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degenerate from lack of dystrophin. GFP-labeled MenSC were
injected intramuscularly, where they fused with murine myoctes
and restored dystrophin in the sarcolemma of muscle fibers (Cui
et al., 2007). Similarly, MenSC fuse with myocytes in co-culture
and subsequently express dystrophin.
MenSC can stimulate the regeneration of pancreatic islet β
cells in a murine model (Wu et al., 2014). MenSC transplantation
enhanced differentiation of endogenous endocrine progenitor
cells into β-cells resulting in more normal islet morphology
and structure, with improved hyperglycemia, glucose tolerance,
insulin levels, body weight and survival rate. Although not
investigated inflammation reduced by MenSC may have also
contributed to the observed results.
In summary, MenSC show potential in regenerative medicine,
with early studies suggesting capacity to influence tissue
regeneration by paracrine mechanism, fusion and enhancement
of endogenous tissue stem cell function.
Extracellular Vesicles as a Key Player of MenSC
Reparative Function
Increasingly, the effects of MSC are attributed to their ability to
secret extracellular vesicles (EVs), including exosomes (Murray
and Krasnodembskaya, 2019). MenSCs also produce functionally
active EVs that are homogeneous in size (30–170 nM) and
express CD81, CD63, and TSG101 (Dalirfardouei et al., 2018).
MenSC-EVs contain 895 proteins involved in complement
activation, antigen processing and presentation, regulation
of adaptive and innate immune responses, apoptosis control
and signaling pathways (Marinaro et al., 2019). Licensing
MenSCs with pro-inflammatory cytokines such as IFN-γ
modulates EV protein cargo, increasing proteins involved in
antigen processing and presentation, and miRNA content.
MenSC-derived EVs also express high levels of ICAM-1,
angiopoetin-2, angiogenin, osteoprotegerin, IL-6, and IL-8.
In a mouse model of fulminant hepatic failure, pre-treatment
with MenSC-exosomes showed higher survival rates, with
reduced serum liver enzymes and pro-inflammatory cytokines,
and well-organized hepatic structure (Chen et al., 2017a).
Hepatocyte apoptosis and proliferation of liver macrophages
were reduced. In a rat model of diabetes, MenSC-derived
EVs were tracked in, and enhanced the number of pancreatic
β cell islets and raised serum insulin, without impact on
non-fasting blood glucose (Mahdipour et al., 2019). MenSC-
derived exosomes impacted wound healing in a mouse
model of diabetes through M2 macrophage polarization,
induction of neoangiogenesis and re-epithelialization
(Dalirfardouei et al., 2019).
In summary, the beneficial impacts of MenSC treatment are
mostly attributed to the anti-inflammatory properties of MenSC-
derived EVs. In some settings the modulatory effects of EVs
were superior to the use of intact MenSC. Therapeutic utilization
of MenSC-EVs might be advantageous over whole cells by
improving the therapeutic index, by introduction of less protein,
avoidance of allo- and xenogeneic reactions and their off-the-
shelf potential. Nonetheless, their nano-scale size results in rapid
clearance from the body necessitating repeated administration
in large quantities, although therapy targeted to damaged tissue
may overcome this potential challenge. Taken together, MenSC
may qualify as a promising therapeutic cell type for future clinical
applications. Nevertheless, as with any other treatment modality,
the safety of MenSC in the clinical settings needs addressing.
CLINICAL TRANSLATION OF eMSC AND
MenSC
There are hundreds of clinical trials using MSC either in progress
or completed and thousands of patients have been treated. Apart
from several spectacular successes the overall results of these
clinical trials have been underwhelming (Prockop et al., 2014).
MSC were rushed to the clinic before many issues were resolved,
including their mechanism of action and the heterogeneity of
MSC products. Heterogeneity arises from variability in isolation
methods and during culture expansion (Prockop et al., 2014).
Thawing cryostored MSC induces cell injury lasting up to 24 h
(Moll et al., 2016), suggesting a lack of fitness for purpose of
culture-expanded, thawed MSC (Galipeau and Sensebe, 2018).
There is also a need for potency assays based on MSC mechanism
of action in vivo (Prockop et al., 2014; Galipeau and Sensebe,
2018). These are important considerations for investigators
seeking to translate eMSC and MenSC as cell-based therapies.
Serum Free Culture Protocols
The clinical translation of human MSC depends upon largescale
production of a homogeneous cell population that is safe
and reproducible. Factors contributing to a heterogeneous
population are isolation protocol, culture medium and culture
environment. The discovery of a single surface marker for
human eMSC, SUSD2, has enabled relatively easy purification of
a homogeneous starting population. Choice of culture medium
and environment majorly influence the generation of large
scale homogeneous eMSC and MSC from other sources utilized
for clinical use. Until recently, MSC including eMSC have
been cultured in fetal calf serum (FCS) containing medium
in 20% O2 environment (Schwab and Gargett, 2007). FCS
provides extracellular matrix, growth factors, hormones and
many other nutrients promoting cell grow and proliferation
(Cantor, 2019). However, FCS is not a defined source of
nutrients with batch to batch variation and presence of unknown
components that contribute to heterogeneity (Shahdadfar
et al., 2005). Some FCS components induce differentiation,
reducing the population of potent MSC (Shahdadfar et al., 2005;
Labome, 2012). The use of FCS for in vitro MSC expansion
also carries a rare risk of xeno-immunization and zoonotic
transmission (Hawkes, 2015). Defined medium devoid of
FCS is required to produce homogeneous, undifferentiated
potent MSC using good manufacturing practices (GMP) for
safe use in humans. Replacing FCS with human products
including human serum, platelet-poor or -rich plasma and
platelet lysate have been used (Dessels et al., 2016). Although
more physiological, these alternatives have similar composition
variability as FCS and may also induce differentiation, resulting
in inconsistent, non-reproducible cell products. Gene profiling
of primary CD140b+CD146+ eMSC showed distinct differences
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to endometrial stromal fibroblasts (CD140b+CD146 −) (Spitzer
et al., 2012) and extensive eMSC cultivation in FCS medium in
20% O2 led down-regulation of 81% of eMSC-related genes and
up-regulation of 55% of fibroblast-associated genes, verifying
culture-induced spontaneous differentiation and reduced
functionality (Barragan et al., 2016; Gargett and Gurung, 2016).
A defined medium and physiological O2 environment that
generates homogeneous undifferentiated eMSC which are
efficacious, safe and reproducible under cGMP guidelines would
be appropriate for clinical applications such as pelvic organ
prolapse and Asherman’s syndrome.
While various serum-free media are available for culturing
human MSC, vast research shows that “one size does not
fit all,” indicting the need to identify the specific niche
environment for eMSC. Indeed, eMSC attachment and growth
were best supported by a fibronectin matrix in xeno-free DMEM
supplemented with FGF2 and EGF (SFM) in 5% O2, compared
to other serum-free commercial media, Lonza-TP-SF and Stem
Pro-XF giving similar growth rates to serum-containing medium
(Rajaraman et al., 2013). Despite this, like all MSC, the expanded
SUSD2+ eMSC spontaneously differentiated to non-clonogenic
stromal fibroblasts with loss of the eMSC surface markers
SUSD2, CD140b, and CD146 indicating cellular heterogeneity
and decreased potency (Gurung et al., 2018b).
Small Molecules to Maintain
Undifferentiated eMSC State
Understanding the intrinsic signaling pathways involved in
stem-cell fate, self-renewal, proliferation and differentiation,
and manipulating them using chemical approaches enables
generation of homogeneous potent cells for cell-based therapies
(Xu et al., 2008; Li and Ding, 2010). Chemically defined
media needs optimization for each cell type using relative cell-
growth as a guide. Augmenting SFM with a small molecule
(A83-01) targeting the transforming growth factor-β1 receptor
(TGFβR) signaling pathway involved in cellular differentiation
and enhanced cell growth, mitigated loss of undifferentiated,
clonogenic eMSC, overcoming this major bottleneck for clinical
translation of eMSC (Gurung et al., 2015, 2018b). A83-01
maintained ISCT properties of eMSC, promoted proliferation
of homogeneous SUSD2+ eMSC and prevented apoptosis
and senescence. Correlation between SUSD2 expression and
TGFβ-induced senescence and cell death was also demonstrated
in cancer cells using small interfering RNA and TGFβ
(Zhang et al., 2017). The potency of A83-01-treated eMSC
was further validated by transcriptome profiling, providing
insight into the biological nature of eMSC and the probable
therapeutic mode of action (Gurung et al., 2015, 2018b). The
complexity of TGFβR signaling in eMSC was defined through
identification of ∼1200 differentially regulated genes by A83-
01 involved in anti-inflammatory responses, angiogenesis, cell
migration and proliferation, collagen fibril and extracellular
matrix organization, anti-fibrosis and anti-apoptosis (Gurung
et al., 2018b). The potency of A83-01-treated eMSC was
established by demonstrating increased expression of recently
described bmMSC potency genes; TWIST1, TWIST2, JAG1,
LIFR, and SLIT2 (Samsonraj et al., 2015; Gurung et al., 2018b).
These and our previous findings also highlighted the need for
additional surface markers to identify potent MSC and for
specific tissues (Rajaraman et al., 2013; Gurung et al., 2015, 2018b;
Samsonraj et al., 2015).
The reparative and regenerative capacity of MSC is mainly
driven by the secretome or EVs that promote angiogenesis,
ECM regulation, immunoregulation and antimicrobial activity.
Transcriptional profiling of A83-01-treated eMSC revealed
important cellular secretome-regulating genes involved in
angiogenesis, anti-fibrosis and immunomodulation; HGF,
VCAM1, PGF, HPSE, SOD3, SOD2, and SOD1. Secretome
analysis of the conditioned medium supported transcriptional
findings with increased HGF, PTX3, CCL2, IGFBP-2, CCL2,
GM-CSF, IGFBP-2, DKK-1, and EGF and decreased THBS1,
EMMPRIN, and OPN. HLA-G, a nonclassical MHC-I molecule,
and immunomodulatory cytokine functioning at the maternal-
fetal interface and some immune privileged adult tissues, was
ubiquitously expressed in A83-01-treated eMSC, together with
HLA-A-C and HLA-E and F, but not HLA-II, an indicator
of good tolerance for allogeneic transplantation. HLA-G has
been identified in several MSC types (Selmani et al., 2008;
Yang et al., 2012; Naji et al., 2013; Ding et al., 2016), and
together with other MHC-I molecules correlates directly to
their immunosuppressive effect (Yang et al., 2012). These
molecules are surrogate prognostic factors used to monitor
disease progression or efficacy of transplantation (Nasef et al.,
2007). Likewise, RNA-sequencing revealed the first evidence of
the ability of A83-01-treated eMSC to secrete exosomes (Gurung
et al., 2018b), that may function in their paracrine action. Further
transcriptome analysis showed evidence of the antimicrobial
potential of A83-01-treated eMSC partially through the secretion
of antimicrobial peptides (AMPs), chromogranin B, liver
enriched AMP-2 and secretogranin II (Gurung et al., 2018b).
Taken together, these findings signify the clinical potential of
eMSC and open avenues to examine their use in regenerative
medicine as an “off the shelf ” as well as cell-derived therapy.
Safety of eMSC
Spontaneous transformation of MSC is a potential concern for
therapeutics, although thorough investigations of earlier studies
showed cellular-cross contamination. To date, no cancer due to
primary-culture expanded MSC, has been diagnosed in human
clinical trials. Nonetheless, the risk of such potential events
should be investigated by utilizing surrogate assays, such as
telomere length, pluripotency genes, tumor formation, genomic
instability, karyotyping and DNA damage response through
transcriptomics and in vitro and in vivo assays. A83-01-expanded
eMSC promote telomere stability through TERC (Telomerase
RNA Component), TERF1 and 2 (Telomeric Repeat Binding
Factors 1 and 2), TINF2 (TERF1 Interacting Nuclear Factor
2), TERF2IP (TERF2 Interacting Protein), TNKS (Tankyrase)
and POT1 (Protection of Telomere 1) which collaborate to
regulate telomere length and protect cells from chromosomal
damage (Gurung et al., 2018b). Using our isolation and expansion
protocol, SUSD2+ eMSC do not express pluripotency-associated
genes, unlike hESC and iPSCs with unlimited growth and
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tumorigenic potential (Gurung et al., 2015; Gurung et al., 2018b).
Although SFM/5%O2/A83-01 culture-expanded eMSC survived
longer in vivo than culture in FCS/20%O2 medium, their lifespan
was limited and tumors were not detected (Gurung et al.,
2018a). Considerable progress has been made in developing




Age of donor affects many of MSC functions; cytokine secretion,
paracrine activity, anti-apoptotic mechanisms, hematopoietic
stem cell supporting capacity and proliferation rate, all of
which reduce with aging (Alt et al., 2012). However, the
proliferative capacity of MenSC does not appear donor-
dependent in individuals aged up to 40 years, but MenSC from
older donors had a weaker potential for long-term passaging
(Chen et al., 2015).
Passage Number
Menstrual blood can be processed up to 72 h after collection
without significant change in properties of the plastic adherent
MenSC (Liu et al., 2018). As mentioned, culture expansion
of MSC is required to obtain enough cells for preclinical
or clinical applications. The proliferation rate of MenSC
gradually decreased with increasing passage number (Chen
et al., 2015), with highly passaged cells increasing in size, losing
fibroblastic morphology and appearing senescent. Important
signaling molecules, including MAPK, molecules involved in
carcinogenesis (PPAR and P53) and immune responses changed
with MenSC passage number. Passaging induces aging of MenSC
and alters genes involved in transcriptional regulation, stress
response, cell proliferation, development and apoptosis, and
karyotype at high passages (P20). MenSC underwent aging after
45 PD (Zemel’ko et al., 2011), but even after 68 PDs of a single
MenSC sample, maintained a normal karyotype and did not
develop tumors (Meng et al., 2007). Multiplex ligation-dependent
probe amplification of MenSC genomic DNA at passages
two and twelve showed that MenSC maintained a diploid
phenotype without chromosomal aberrations (Khanmohammadi
et al., 2014), consistent with other reports of a normal female
karyotype without chromosomal aberrations using standard
cytogenetics at passage 12 (Cui et al., 2007; Patel et al., 2008).
Pluripotency protein expression reduced during passaging of
MenSCs, from 97.5% OCT-4+ cells at the first passage to 19.4%
at passage twelve (Khanmohammadi et al., 2014), important for
clinical translation. These observations warrant standardization
of MenSC isolation and culture protocols for clinical applications.
Safety of MenSC
The risk of tumorigenicity, toxicity, autoimmunity, and/or
endometriosis following MenSCs injection are crucial safety
issues to be established before using MenSC in the clinic.
Angiogenic activity of MenSC, raises concern of promoting
tumor progression. In a C6 model of rat glioma MenSCs
not only failed to stimulate, but also inhibited tumor growth
(Han et al., 2009). MenSCs showed no tumor formation in
a xenograft rat model of brain stroke with no concurrent
immunosuppression (Borlongan et al., 2010). Several
acute and chronic tumorigenicity/toxicity experiments in
immunocompromised mice using MenSC in clinically relevant
doses showed no toxic effects on body and organ weight,
biochemistry following necropsy or histopathological changes at
injection sites (Bockeria et al., 2013). Concerns of ectopic bone
formation on clinical application of bmMSC, are mitigated by
the weak osteogenic differentiation capacity of MenSC and could
be advantageous for clinical translation.
The next step prior to clinical development of MenSC is to
undertake cell tracking of reliably labeled MenSC in vivo and
determining their mechanism of action. Also important is the
development of relevant large animal pre-clinical models of the
targeted disease for evaluating MenSC, to improve the likelihood
of translating rodent studies into clinical practice. In 2008,
four multiple sclerosis patients were injected both intrathecally
and intravenously with in vitro expanded allogeneic MenSC.
Functional and radiological evaluations demonstrated no disease
status progression and none of the treated patients showed
allergic reactions or ectopic tissue formation (Zhong et al., 2009).
No adverse effects were observed in the patients 4 years later in
the last reported follow up (Bockeria et al., 2013). Clearly more
investigation is required to determine the safety of MenSC for
clinical translation.
Identification of eMSC potency makers and serum-free
expansion media have enabled gene sequencing of the primary
cells and their expanded progeny (Spitzer et al., 2012; Barragan
et al., 2016; Gurung et al., 2018b). Comprehensive RNA-
seq analysis of SFM/5%O2/A83-01-treated eMSC described
the gene expression profiles and uncovered vast range of
regulatory pathways which not only aided in understating their
mechanism of action but also suggested their potential for
broader applications. Much progress are made in understanding
the in vitro and in vivo roles of eMSC, setting a strong foundation
for clinical application. Further research to understand and
validate eMSC’s potential through careful titration of assays and
selection of animal models relative to their potential use is vital.
SUMMARY
eMSC and MenSC have fulfilled the ISCT criteria for MSC, but
thus far, no comparative study has been performed to delineate
the potential link between these two MSC types. Nonetheless,
considering that eMSC comprise a small cell population residing
around endometrial blood vessels while MenSC represent
majority of endometrial stromal cells, it seems that the latter
is more heterogeneous. Although multi-differentiation capacity
of eMSC and MenSC has been documented in vitro, the
reparative properties of these cells in vivo seem to stem
from their paracrine rather than differentiation capacity and
integration into tissue. Akin to MSC from other sources, MenSC
and eMSC have profound immunomodulatory effects and
attenuate inflammation, although there are distinct differences
highlighting their unique tissue of origin. eMSC and MenSC
have been evaluated in numerous preclinical animal models of
disease showing substantial angiogenic, anti-fibrotic and anti-
inflammatory effects although it is too early to draw a firm
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conclusion on the same impacts in clinical settings. Culture
protocols have been developed that maintain perivascular eMSC
in the undifferentiated state during culture expansion, which
now need testing in animal models to determine if this
more homogeneous MSC product further improves in vivo
angiogenesis, antifibrosis, anti-inflammatory and prohealing
effects. Both eMSC, easily procured without anesthetic, and non-
invasively obtained MenSC, imbued with both reparative and
immunomodulatory properties are likely promising therapeutic
cell types for future clinical applications. Nevertheless, multiple
variables need to be standardized particularly heterogeneity of
MenSC and the safety and therapeutic potency of eMSC and
MenSC in clinical settings needs to be extensively addressed.
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